AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesTechnology, Industry, AgricultureNamed GroupsHealth Care
SirolimusImmunosuppressive AgentsTacrolimusKidney TransplantationCyclosporineMycophenolic AcidCalcineurinGraft RejectionDrug SubstitutionLymphangioleiomyomatosisAngiomyolipomaTOR Serine-Threonine KinasesGraft SurvivalLymphangiomyomaInjections, IntraocularCoronary RestenosisDrug Therapy, CombinationTreatment OutcomeChyleLiver TransplantationPolyenesTransplantation, HomologousDrug-Eluting StentsCreatinineKidneyCardiovascular AgentsTime FactorsDrug MonitoringIslets of Langerhans TransplantationDrug ImplantsGlomerular Filtration RateTransplantationFluorescence Polarization ImmunoassayAntibiotics, AntineoplasticStentsImmunosuppressionThrombotic MicroangiopathiesTubulin ModulatorsOxaloacetic AcidCoated Materials, BiocompatibleCitrus paradisiPolycystic Kidney, Autosomal DominantAzathioprineAcetic AnhydridesHeart TransplantationFollow-Up StudiesDrug InteractionsUnrelated DonorsRetrospective StudiesAntilymphocyte SerumTuberous SclerosisOral UlcerRenal InsufficiencyKidney Function TestsPerivascular Epithelioid Cell NeoplasmsRibosomal Protein S6 Kinases, 70-kDaPaclitaxelBiliary FistulaBiopsyClinical AuditAdrenal Cortex HormonesKetoconazoleOligomenorrheaTransplantation ConditioningRespiratory System AgentsMucoralesProspective StudiesSteroidsPostoperative ComplicationsAbsorbable ImplantsCytochrome P-450 CYP3ALiving DonorsBenzenesulfonatesDose-Response Relationship, DrugIntention to Treat AnalysisGraft Occlusion, VascularCoronary AngiographyProteinuria
Sirolimus
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Tacrolimus
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
Kidney Transplantation
The transference of a kidney from one human or animal to another.
Cyclosporine
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Mycophenolic Acid
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Calcineurin
A CALCIUM and CALMODULIN-dependent serine/threonine protein phosphatase that is composed of the calcineurin A catalytic subunit and the calcineurin B regulatory subunit. Calcineurin has been shown to dephosphorylate a number of phosphoproteins including HISTONES; MYOSIN LIGHT CHAIN; and the regulatory subunits of CAMP-DEPENDENT PROTEIN KINASES. It is involved in the regulation of signal transduction and is the target of an important class of immunophilin-immunosuppressive drug complexes.
Graft Rejection
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Drug Substitution
The practice of replacing one prescribed drug with another that is expected to have the same clinical or psychological effect.
Lymphangioleiomyomatosis
A disease characterized by the progressive invasion of SMOOTH MUSCLE CELLS into the LYMPHATIC VESSELS, and the BLOOD VESSELS. The majority of the cases occur in the LUNGS of women of child-bearing age, eventually blocking the flow of air, blood, and lymph. The common symptom is shortness of breath (DYSPNEA).
Angiomyolipoma
A benign tumor containing vascular, adipose, and muscle elements. It occurs most often in the kidney with smooth muscle elements (angiolipoleiomyoma) in association with tuberous sclerosis. (Dorland, 27th ed)
TOR Serine-Threonine Kinases
A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.
Graft Survival
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
Lymphangiomyoma
A tumorlike condition characterized by SMOOTH MUSCLE and ENDOTHELIUM proliferation of LYMPHATIC VESSELS and LYMPH NODES in the MEDIASTINUM and retroperitoneum, also in the lung. It may be manifested by chylous PLEURAL EFFUSION and ASCITES.
Injections, Intraocular
The administration of substances into the eye with a hypodermic syringe.
Coronary Restenosis
Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
Drug Therapy, Combination
Therapy with two or more separate preparations given for a combined effect.
Treatment Outcome
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Chyle
An opaque, milky-white fluid consisting mainly of emulsified fats that passes through the lacteals of the small intestines into the lymphatic system.
Liver Transplantation
The transference of a part of or an entire liver from one human or animal to another.
Polyenes
Hydrocarbons with more than one double bond. They are a reduced form of POLYYNES.
Transplantation, Homologous
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Drug-Eluting Stents
Stents that are covered with materials that are embedded with chemicals that are gradually released into the surrounding milieu.
Creatinine
Kidney
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Cardiovascular Agents
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
Time Factors
Elements of limited time intervals, contributing to particular results or situations.
Drug Monitoring
The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.
Islets of Langerhans Transplantation
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
Drug Implants
Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug.
Glomerular Filtration Rate
The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance.
Transplantation
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
Fluorescence Polarization Immunoassay
Fluoroimmunoassay where detection of the hapten-antibody reaction is based on measurement of the increased polarization of fluorescence-labeled hapten when it is combined with antibody. The assay is very useful for the measurement of small haptenic antigens such as drugs at low concentrations.
Antibiotics, Antineoplastic
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Stents
Devices that provide support for tubular structures that are being anastomosed or for body cavities during skin grafting.
Immunosuppression
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
Thrombotic Microangiopathies
Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.
Tubulin Modulators
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.
Oxaloacetic Acid
A dicarboxylic acid ketone that is an important metabolic intermediate of the CITRIC ACID CYCLE. It can be converted to ASPARTIC ACID by ASPARTATE TRANSAMINASE.
Coated Materials, Biocompatible
Biocompatible materials usually used in dental and bone implants that enhance biologic fixation, thereby increasing the bond strength between the coated material and bone, and minimize possible biological effects that may result from the implant itself.
Citrus paradisi
A plant species of the genus CITRUS, family RUTACEAE that produces the familiar grapefruit. There is evidence that grapefruit inhibits CYTOCHROME P-450 CYP3A4, resulting in delayed metabolism and higher blood levels of a variety of drugs.
Polycystic Kidney, Autosomal Dominant
Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.
Azathioprine
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
Acetic Anhydrides
Compounds used extensively as acetylation, oxidation and dehydrating agents and in the modification of proteins and enzymes.
Heart Transplantation
The transference of a heart from one human or animal to another.
Follow-Up Studies
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Drug Interactions
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
Unrelated Donors
Providers of tissues for transplant to non-related individuals.
Retrospective Studies
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Antilymphocyte Serum
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Tuberous Sclerosis
Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.
Oral Ulcer
A loss of mucous substance of the mouth showing local excavation of the surface, resulting from the sloughing of inflammatory necrotic tissue. It is the result of a variety of causes, e.g., denture irritation, aphthous stomatitis (STOMATITIS, APHTHOUS); NOMA; necrotizing gingivitis (GINGIVITIS, NECROTIZING ULCERATIVE); TOOTHBRUSHING; and various irritants. (From Jablonski, Dictionary of Dentistry, 1992, p842)
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
Kidney Function Tests
Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine.
Perivascular Epithelioid Cell Neoplasms
A family of mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. These cells do not have a normal anatomic homolog. (From Fletcher CDM, et. al., World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone, 2002).
Ribosomal Protein S6 Kinases, 70-kDa
A family of ribosomal protein S6 kinases that are considered the major physiological kinases for RIBOSOMAL PROTEIN S6. Unlike RIBOSOMAL PROTEIN S6 KINASES, 90KDa the proteins in this family are sensitive to the inhibitory effects of RAPAMYCIN and contain a single kinase domain. They are referred to as 70kDa proteins, however ALTERNATIVE SPLICING of mRNAs for proteins in this class also results in 85kDa variants being formed.
Paclitaxel
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Biliary Fistula
Abnormal passage in any organ of the biliary tract or between biliary organs and other organs.
Biopsy
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Clinical Audit
A detailed review and evaluation of selected clinical records by qualified professional personnel to improve the quality of patient care and outcomes. The clinical audit was formally introduced in 1993 into the United Kingdom's National Health Service.
Adrenal Cortex Hormones
Ketoconazole
Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients.
Oligomenorrhea
Abnormally infrequent menstruation.
Transplantation Conditioning
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Respiratory System Agents
Drugs used for their effects on the respiratory system.
Mucorales
An order of zygomycetous fungi, usually saprophytic, causing damage to food in storage, but which may cause respiratory infection or MUCORMYCOSIS in persons suffering from other debilitating diseases.
Prospective Studies
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Steroids
A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
Absorbable Implants
Implants constructed of materials designed to be absorbed by the body without producing an immune response. They are usually composed of plastics and are frequently used in orthopedics and orthodontics.
Cytochrome P-450 CYP3A
A cytochrome P-450 suptype that has specificity for a broad variety of lipophilic compounds, including STEROIDS; FATTY ACIDS; and XENOBIOTICS. This enzyme has clinical significance due to its ability to metabolize a diverse array of clinically important drugs such as CYCLOSPORINE; VERAPAMIL; and MIDAZOLAM. This enzyme also catalyzes the N-demethylation of ERYTHROMYCIN.
Living Donors
Non-cadaveric providers of organs for transplant to related or non-related recipients.
Benzenesulfonates
Organic salts and esters of benzenesulfonic acid.
Dose-Response Relationship, Drug
The relationship between the dose of an administered drug and the response of the organism to the drug.
Intention to Treat Analysis
Strategy for the analysis of RANDOMIZED CONTROLLED TRIALS AS TOPIC that compares patients in the groups to which they were originally randomly assigned.
Graft Occlusion, Vascular
Obstruction of flow in biological or prosthetic vascular grafts.
Coronary Angiography
Radiography of the vascular system of the heart muscle after injection of a contrast medium.
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.

High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. (1/4814)

BACKGROUND: Fully adapting a forward genetic approach to mammalian systems requires efficient methods to alter systematically gene products without prior knowledge of gene sequences, while allowing for the subsequent characterization of these alterations. Ideally, these methods would also allow function to be altered in a temporally controlled manner. RESULTS: We report the development of a miniaturized cell-based assay format that enables a genetic-like approach to understanding cellular pathways in mammalian systems using small molecules, rather than mutations, as the source of gene-product alterations. This whole-cell immunodetection assay can sensitively detect changes in specific cellular macromolecules in high-density arrays of mammalian cells. Furthermore, it is compatible with screening large numbers of small molecules in nanoliter to microliter culture volumes. We refer to this assay format as a 'cytoblot', and demonstrate the use of cytoblotting to monitor biosynthetic processes such as DNA synthesis, and post-translational processes such as acetylation and phosphorylation. Finally, we demonstrate the applicability of these assays to natural-product screening through the identification of marine sponge extracts exhibiting genotype-specific inhibition of 5-bromodeoxyuridine incorporation and suppression of the anti-proliferative effect of rapamycin. CONCLUSIONS: We show that cytoblots can be used for high-throughput screening of small molecules in cell-based assays. Together with small-molecule libraries, the cytoblot assay can be used to perform chemical genetic screens analogous to those used in classical genetics and thus should be applicable to understanding a wide variety of cellular processes, especially those involving post-transitional modifications.  (+info)

Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. (2/4814)

The mammalian target of rapamycin (mTOR) has been shown to link growth factor signaling and posttranscriptional control of translation of proteins that are frequently involved in cell cycle progression. However, the role of this pathway in cell survival has not been demonstrated. Here, we report that rapamycin, a specific inhibitor of mTOR kinase, induces G1 cell cycle arrest and apoptosis in two rhabdomyosarcoma cell lines (Rh1 and Rh30) under conditions of autocrine cell growth. To examine the kinetics of rapamycin action, we next determined the rapamycin sensitivity of rhabdomyosarcoma cells exposed briefly (1 h) or continuously (6 days). Results demonstrate that Rh1 and Rh30 cells were equally sensitive to rapamycin-induced growth arrest and apoptosis under either condition. Apoptosis was detected between 24 and 144 h of exposure to rapamycin. Both cell lines have mutant p53; hence, rapamycin-induced apoptosis appears to be a p53-independent process. To determine whether induction of apoptosis by rapamycin was specifically due to inhibition of mTOR signaling, we engineered Rh1 and Rh30 clones to stably express a mutant form of mTOR that was resistant to rapamycin (Ser2035-->Ile; designated mTOR-rr). Rh1 and Rh30 mTOR-rr clones were highly resistant (>3000-fold) to both growth inhibition and apoptosis induced by rapamycin. These results are the first to indicate that rapamycin-induced apoptosis is mediated by inhibition of mTOR. Exogenous insulin-like growth factor (IGF)-I protected both Rh1 and Rh30 from apoptosis, without reactivating ribosomal p70 S6 kinase (p70S6K) downstream of mTOR. However, in rapamycin-treated cultures, the response to IGF-I differed between the cell lines: Rh1 cells proliferated normally, whereas Rh30 cells remained arrested in G1 phase but viable. Rapamycin is known to inhibit synthesis of specific proteins but did not inhibit synthesis or alter the levels of mTOR. To examine the rate at which the mTOR pathway recovered, the ability of IGF-I to stimulate p70S6K activity was followed in cells treated for 1 h with rapamycin and then allowed to recover in medium containing > or =100-fold excess of FK506 (to prevent rapamycin from rebinding to its cytosolic receptor FKBP-12). Our results indicate that, in Rh1 cells, rapamycin dissociates relatively slowly from FKBP-12, with a t1/2 of approximately 17.5 h. in the presence of FK506, whereas there was no recovery of p70S6K activity in the absence of this competitor. This was of interest because rapamycin was relatively unstable under conditions of cell culture having a biological t1/2 of approximately 9.9 h. These results help to explain why cells are sensitive following short exposures to rapamycin and may be useful in guiding the use of rapamycin analogues that are entering clinical trials as novel antitumor agents.  (+info)

Hmo1p, a high mobility group 1/2 homolog, genetically and physically interacts with the yeast FKBP12 prolyl isomerase. (3/4814)

The immunosuppressive drugs FK506 and rapamycin bind to the cellular protein FKBP12, and the resulting FKBP12-drug complexes inhibit signal transduction. FKBP12 is a ubiquitous, highly conserved, abundant enzyme that catalyzes a rate-limiting step in protein folding: peptidyl-prolyl cis-trans isomerization. However, FKBP12 is dispensible for viability in both yeast and mice, and therefore does not play an essential role in protein folding. The functions of FKBP12 may involve interactions with a number of partner proteins, and a few proteins that interact with FKBP12 in the absence of FK506 or rapamycin have been identified, including the ryanodine receptor, aspartokinase, and the type II TGF-beta receptor; however, none of these are conserved from yeast to humans. To identify other targets and functions of FKBP12, we have screened for mutations that are synthetically lethal with an FKBP12 mutation in yeast. We find that mutations in HMO1, which encodes a high mobility group 1/2 homolog, are synthetically lethal with mutations in the yeast FPR1 gene encoding FKBP12. Deltahmo1 and Deltafpr1 mutants share two phenotypes: an increased rate of plasmid loss and slow growth. In addition, Hmo1p and FKBP12 physically interact in FKBP12 affinity chromatography experiments, and two-hybrid experiments suggest that FKBP12 regulates Hmo1p-Hmo1p or Hmo1p-DNA interactions. Because HMG1/2 proteins are conserved from yeast to humans, our findings suggest that FKBP12-HMG1/2 interactions could represent the first conserved function of FKBP12 other than mediating FK506 and rapamycin actions.  (+info)

Interaction of asparagine and EGF in the regulation of ornithine decarboxylase in IEC-6 cells. (4/4814)

Our laboratory has shown that asparagine (ASN) stimulates both ornithine decarboxylase (ODC) activity and gene expression in an intestinal epithelial cell line (IEC-6). The effect of ASN is specific, and other A- and N-system amino acids are almost as effective as ASN when added alone. In the present study, epidermal growth factor (EGF) was unable to increase ODC activity in cells maintained in a salt-glucose solution (Earle's balanced salt solution). However, the addition of ASN (10 mM) in the presence of EGF (30 ng/ml) increased the activity of ODC 0.5- to 4-fold over that stimulated by ASN alone. EGF also showed induction of ODC with glutamine and alpha-aminoisobutyric acid, but ODC induction was maximum with ASN and EGF. Thus the mechanism of the interaction between ASN and EGF is important for understanding the regulation of ODC under physiological conditions. Therefore, we examined the expression of the ODC gene and those for several protooncogenes under the same conditions. Increased expression of the genes for c-Jun and c-Fos but not for ODC occurred with EGF alone. The addition of ASN did not further increase the expression of the protooncogenes, but the combination of EGF and ASN further increased the expression of ODC over that of ASN alone. Western analysis showed no significant difference in the level of ODC protein in Earle's balanced salt solution, ASN, EGF, or EGF plus ASN. Addition of cycloheximide during ASN and ASN plus EGF treatment completely inhibited ODC activity without affecting the level of ODC protein. These results indicated that 1) the increased expression of protooncogenes in response to EGF is independent of increases in ODC activity and 2) potentiation between EGF and ASN on ODC activity may not be due to increased gene transcription but to posttranslational regulation and the requirement of ongoing protein synthesis involving a specific factor dependent on ASN.  (+info)

Cyclosporin A treatment alters characteristics of Ca2+-release channel in cardiac sarcoplasmic reticulum. (5/4814)

Chronic treatment with cyclosporin A (CsA) has been reported (H. S. Banijamali, M. H. ter Keurs, L. C. Paul, and H. E. ter Keurs. Cardiovasc. Res. 27: 1845-1854, 1993; I. Kingma, E. Harmsen, H. E. ter Keurs, H. Benediktsson, and L. C. Paul. Int. J. Cardiol. 31: 15-22, 1991) to induce reversible alterations of contractile properties in rat hearts. To define the molecular mechanisms underlying the physiological alterations, the Ca2+-release channel (CRC) and Ca2+-ATPase from sarcoplasmic reticulum in rats were examined. Ryanodine binding to whole homogenates of rat hearts shows time- and dose-dependent alterations in CRC properties by CsA. On 3 wk of treatment with 15 mg CsA. kg body wt-1. day-1, 1) maximal ryanodine binding (Bmax) decreased, 2) the dissociation constant of ryanodine (Kd) increased, 3) caffeine sensitivity of CRC increased, and 4) ruthenium red sensitivity of CRC decreased. On the other hand, Bmax and Kd of ryanodine binding in rat skeletal muscles were not changed. Ryanodine-sensitive oxalate-supported Ca2+ uptake in whole homogenates was lower in CsA-treated rat hearts than in control hearts, whereas total Ca2+ uptake in the presence of 500 M ryanodine was not changed. Functional experiments with rapamycin and Western blot analysis suggest that the CsA-induced alteration of ryanodine binding is due at least in part to an upregulation of calcineurin. The heart muscle-specific alterations of CRC could be responsible for the previously reported contractile changes of CsA-treated rat hearts.  (+info)

Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. (6/4814)

Costimulation (signal 2) has been proposed to inhibit the induction of T cell clonal anergy by either directly antagonizing negative signals arising from TCR engagement (signal 1) or by synergizing with signal 1 to produce IL-2, which in turn leads to proliferation and dilution of negative regulatory factors. To better define the cellular events that lead to the induction of anergy, we used the immunosuppressive agent rapamycin, which blocks T cell proliferation in late G1 phase but does not affect costimulation-dependent IL-2 production. Our data demonstrate that full T cell activation (signal 1 plus 2) in the presence of rapamycin results in profound T cell anergy, despite the fact that these cells produce copious amounts of IL-2. Similar to conventional anergy (induction by signal 1 alone), the rapamycin-induced anergic cells show a decrease in mitogen-activated protein kinase activation, and these cells can be rescued by culture in IL-2. Interestingly, the rapamycin-induced anergic cells display a more profound block in IL-3 and IFN-gamma production upon rechallenge. Finally, in contrast to rapamycin, full T cell activation in the presence of hydroxyurea (which inhibits the cell cycle in early S phase) did not result in anergy. These data suggest that it is neither the direct effect of costimulation nor the subsequent T cell proliferation that prevents anergy induction, but rather the biochemical events that occur upon progression through the cell cycle from G1 into S phase.  (+info)

p70(S6K) controls selective mRNA translation during oocyte maturation and early embryogenesis in Xenopus laevis. (7/4814)

In mammalian cells, p70(S6K) plays a key role in translational control of cell proliferation in response to growth factors. Because of the reliance on translational control in early vertebrate development, we cloned a Xenopus homolog of p70(S6K) and investigated the activity profile of p70(S6K) during Xenopus oocyte maturation and early embryogenesis. p70(S6K) activity is high in resting oocytes and decreases to background levels upon stimulation of maturation with progesterone. During embryonic development, three peaks of activity were observed: immediately after fertilization, shortly before the midblastula transition, and during gastrulation. Rapamycin, an inhibitor of p70(S6K) activation, caused oocytes to undergo germinal vesicle breakdown earlier than control oocytes, and sensitivity to progesterone was increased. Injection of a rapamycin-insensitive, constitutively active mutant of p70(S6K) reversed the effects of rapamycin. However, increases in S6 phosphorylation were not significantly affected by rapamycin during maturation. mos mRNA, which does not contain a 5'-terminal oligopyrimidine tract (5'-TOP), was translated earlier, and a larger amount of Mos protein was produced in rapamycin-treated oocytes. In fertilized eggs rapamycin treatment increased the translation of the Cdc25A phosphatase, which lacks a 5'-TOP. Translation assays in vivo using both DNA and RNA reporter constructs with the 5'-TOP from elongation factor 2 showed decreased translational activity with rapamycin, whereas constructs without a 5'-TOP or with an internal ribosome entry site were translated more efficiently upon rapamycin treatment. These results suggest that changes in p70(S6K) activity during oocyte maturation and early embryogenesis selectively alter the translational capacity available for mRNAs lacking a 5'-TOP region.  (+info)

Growth hormone-dependent differentiation of 3T3-F442A preadipocytes requires Janus kinase/signal transducer and activator of transcription but not mitogen-activated protein kinase or p70 S6 kinase signaling. (8/4814)

The signals mediating growth hormone (GH)-dependent differentiation of 3T3-F442A preadipocytes under serum-free conditions have been studied. GH priming of cells was required before the induction of terminal differentiation by a combination of epidermal growth factor, tri-iodothyronine, and insulin. Cellular depletion of Janus kinase-2 (JAK-2) using antisense oligodeoxynucleotides (ODNs) prevented GH-stimulated JAK-2 and signal transducer and activator of transcription (STAT)-5 tyrosine phosphorylation and severely attenuated the ability of GH to promote differentiation. Although p42(MAPK)/p44(MAPK) mitogen-activated protein kinases were activated during GH priming, treatment of cells with PD 098059, which prevented activation of these kinases, did not block GH priming. However, antisense ODN-mediated depletion of mitogen-activated protein kinases from the cells showed that their expression was necessary for terminal differentiation. Similarly, although p70(s6k) was activated during GH priming, pretreatment of cells with rapamycin, which prevented the activation of p70(s6k), had no effect on GH priming. However, rapamycin did partially block epidermal growth factor, tri-iodothyronine, and insulin-stimulated terminal differentiation. By contrast, cellular depletion of STAT-5 with antisense ODNs completely abolished the ability of GH to promote differentiation. These results indicate that JAK-2, acting specifically via STAT-5, is necessary for GH-dependent differentiation of 3T3-F442A preadipocytes. Activation of p42(MAPK)/p44(MAPK) and p70(s6k) is not essential for the promotion of differentiation by GH, although these signals are required for GH-independent terminal differentiation.  (+info)

Abstract 2808: The long-term efficacy of Sirolimus- and Paclitaxel-Eluting Stents as Compared to Bare Metal Stents in Patients...Abstract 2808: The long-term efficacy of Sirolimus- and Paclitaxel-Eluting Stents as Compared to Bare Metal Stents in Patients...
Background Diabetics are known to have an accelerated and more aggressive form of atherosclerosis. Both paclitaxel- and sirolimus-eluting stents (PES and SES respectively) showed to reduce clinical and angiographic restenosis as compared to bare metal stents (BMS) up until 1 year. Due to the different mechanisms of action of both drugs and the interference with the PI3-kinase pathway, which is degraded in diabetic patients, it is currently unknown which device is the best option to treat these high-risk patients.. Methods The present study compares the 2-year outcome of a series of 708 consecutive diabetic patients (25% insulin treated) treated with either a BMS, a SES or a PES, as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries respectively.. Results All-cause mortality did not differ significantly between the 3 groups. As compared to BMS, the use of PES but not SES, was ...
http://circ.ahajournals.org/content/114/Suppl_18/II_587.5
Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: Three-year results of the RAVEL trial<...
TY - JOUR. T1 - Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents. T2 - Three-year results of the RAVEL trial. AU - Fajadet, Jean. AU - Morice, Marie Claude. AU - Bode, Christoph. AU - Barragan, Paul. AU - Serruys, Patrick W.. AU - Wijns, William. AU - Constantini, Constantino R.. AU - Guermonprez, Jean Léon. AU - Eltchaninoff, Hélène. AU - Blanchard, Didier. AU - Bartorelli, Antonio. AU - Laarman, Gert Jan. AU - Perin, MarcoAntonio. AU - Sousa, J. Eduardo. AU - Schuler, Gerhard. AU - Molnar, Ferenc. AU - Guagliumi, Giulio. AU - Colombo, Antonio. AU - Hayashi, Ernesto Ban. AU - Wülfert, Egon. PY - 2005/3/1. Y1 - 2005/3/1. N2 - Background - The use of sirolimus-eluting coronary stents has been associated with a nearly complete elimination of restenosis at 6 months and with a very low 1-year incidence of major adverse cardiac events (MACE). This analysis examined whether these beneficial effects persist over the longer term. Methods and Results - This multicenter ...
https://moh-it.pure.elsevier.com/en/publications/maintenance-of-long-term-clinical-benefit-with-sirolimus-eluting-
Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide...
TY - JOUR. T1 - Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population. T2 - A report from the e-SELECT (Multi-center Post-Market Surveillance) registry. AU - Urban, Philip. AU - Abizaid, Alexandre. AU - Banning, Adrian. AU - Bartorelli, Antonio L.. AU - Baux, Ana Cebrian. AU - Davk, Vladimr. AU - Ellis, Stephen. AU - Gao, Runlin. AU - Holmes, David. AU - Jeong, Myung Ho. AU - Legrand, Victor. AU - Neumann, Franz Josef. AU - Nyakern, Maria. AU - Spaulding, Christian. AU - Worthley, Stephen. PY - 2011/3/29. Y1 - 2011/3/29. N2 - Objectives: The aim of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in a large, unselected population treated with sirolimus-eluting stents (SES). Background: Stent thrombosis and MB are major potential complications of drug-eluting stent implantation. Their relative incidence and predisposing factors among large populations treated ...
https://mayoclinic.pure.elsevier.com/en/publications/stent-thrombosis-and-bleeding-complications-after-implantation-of
Cordis Announces Discontinuation of NEVOâ„¢ Sirolimus-Eluting Coronary StentCordis Announces Discontinuation of NEVOâ„¢ Sirolimus-Eluting Coronary Stent
BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO™ Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. The company will also stop the manufacture of CYPHER® and CYPHER SELECT® Plus Sirolimus-Eluting Coronary Stents by the end of 2011.. Due to evolving market dynamics in the drug-eluting stent (DES) business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market, said Seth Fischer, Company Group Chair and Worldwide Chairman, Cordis Corporation. Cordis has been a leader in establishing many markets including diagnostic and guiding catheters, bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular disease and arrhythmias. These ...
https://www.mdtmag.com/news/2011/06/cordis-announces-discontinuation-nevo%C3%A2%E2%80%9E%C2%A2-sirolimus-eluting-coronary-stent
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma<...
TY - JOUR. T1 - A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. AU - Witzig, T. E.. AU - Reeder, C. B.. AU - Laplant, B. R.. AU - Gupta, M.. AU - Johnston, P. B.. AU - Micallef, I. N.. AU - Porrata, L. F.. AU - Ansell, S. M.. AU - Colgan, J. P.. AU - Jacobsen, E. D.. AU - Ghobrial, I. M.. AU - Habermann, T. M.. N1 - Funding Information: Research supported in part by the NIH grants CA127433, CA112904 and CA97274, and the Predolin Foundation.. PY - 2011/2. Y1 - 2011/2. N2 - The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkins lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). The goal of this trial was to learn the antitumor activity and toxicity of single-agent everolimus in patients with relapsed/refractory aggressive NHL. Patients received everolimus 10 mg PO daily. Response was assessed after two and six cycles, ...
https://mayoclinic.pure.elsevier.com/en/publications/a-phase-ii-trial-of-the-oral-mtor-inhibitor-everolimus-in-relapse-2
Randomized Study Comparing Endeavor With Cypher Stents (PROTECT) - Full Text View - ClinicalTrials.govRandomized Study Comparing Endeavor With Cypher Stents (PROTECT) - Full Text View - ClinicalTrials.gov
The PROTECT TRIAL is a randomized stent trial with 8800 patients in approximately 200 hospitals, which is designed to evaluate whether the Endeavor stent PROTECTS against late stent thrombosis resulting in less deaths and myocardial infarctions.. Study Stents:. Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System or next generation model Cordis Cypher® Sirolimus-eluting Coronary Stent, Cordis Cypher Select® Sirolimus-eluting Coronary Stent or next generation model. Primary Objective: To compare overall stent thrombosis rate of the Endeavor® Zotarolimus Eluting Coronary Stent System versus the Cypher® Sirolimus-eluting Coronary Stent in a patient population requiring stent implantation. Secondary Objective: To compare the composite endpoint of total death or cardiac death combined with the number of patients with all non-fatal myocardial infarctions as well as the number of patients with large non-fatal myocardial infarctions for Endeavor® Zotarolimus Eluting Coronary Stent System ...
https://clinicaltrials.gov/ct2/show/NCT00476957?term=heart+attack&lup_s=04%2F22%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14
Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients - Full...Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients - Full...
A prospective multicenter registry in real-world Japanese patients undergoing DAPT for three months after stenting. To assess the long-term safety of Endeavor Zotarolimus-eluting stent through noninferiority in the primary endpoint between two different continuous regimen (three and twelve months) groups of DAPT after stenting with Endeavor Zotarolimus-eluting stent in real-world Japanese patients and to examine the optimal duration of DAPT after stenting with Endeavor Zotarolimus-eluting stent. The long-term DAPT group in the present clinical study (to be appropriated from the post-marketing surveillance of Endeavor) should consist of consecutive patients undergoing DAPT for twelve months after stenting, while the short-term DAPT group (to be newly registered in the present clinical study) should consist of patients who are instructed to undergo DAPT for three months after stenting ...
https://clinicaltrials.gov/ct2/show/NCT01325935?term=Cerebral+Arteriosclerosis&rank=10
PRIME PubMed | The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in micPRIME PubMed | The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mic
PubMed journal article The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mic were found in PRIME PubMed. Download Prime PubMed App to iPhone, iPad, or Android
https://www.unboundmedicine.com/medline/citation/17331841/The_effect_of_immunosuppressive_drug_rapamycin_on_regulatory_CD4+CD25+Foxp3+T_cells_in_mice_
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS...SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS...
RRISC Trial Reduction of Restenosis In Saphenous vein grafts with Cypher sirolimus-eluting stent Prospective, randomized, double-blind, non industry sponsored, trial comparing sirolimus-eluting stents vs. bare metal stents. Prospective, randomized, double-blind, non industry sponsored, trial comparing sirolimus-eluting stents vs. bare metal stents. 75 patients with 96 lesions localized in 80 diseased saphenous vein grafts were included 75 patients with 96 lesions localized in 80 diseased saphenous vein grafts were included Primary endpoint : in-stent late loss Primary endpoint : in-stent late loss Secondary endpoints: Secondary endpoints:  Clinical events (death, MI, TLR, TVR)  Binary angiographic restenosis in-stent/in-segment  IVUS measured neo-intimal hyperplasia volume
https://slideplayer.com/slide/8601543/
Patent US5985890 - Rapamycin derivatives - Google PatentsPatent US5985890 - Rapamycin derivatives - Google Patents
Rapamycin derivatives selected among 32(S)-dihydro-rapamycin derivatives and 32-deoxo-rapamycin compounds. Rapamycin derivatives are disclosed of the formula: ##STR1## wherein the variables are in the specification.
http://www.google.com/patents/US5985890?dq=5920316
Therapeutic Drug Monitoring of Sirolimus,Correlation With Laboratory Parameters In Transplant PatientsTherapeutic Drug Monitoring of Sirolimus,Correlation With Laboratory Parameters In Transplant Patients
Sirolimus is a potent immunosuppressive agent administered as prophylactic agent to prevent rejection after organ transplantation. Sirolimus must be used within a narrow therapeutic window. Due to inter- and intra-variability, sirolimus blood concentrations may be affected, therefore, there is no possibility of predicting the sirolimus blood concentrations based on the dose patients received. Therapeutic drug monitoring (TDM) of whole blood is an important part of immunosuppressive therapy and is mandatory for sirolimus dosage individualization. The objective of this study was to present a validated method for the analysis of sirolimus in human blood by LC/MS spectrometry and also evaluation of correlation between blood sirolimus concentration and laboratory parameters. We examined a group of 32 patients receiving sirolimus at different stages after organ (kidney, liver or pancreas) transplantation. The mean sirolimus concentration was 10.2 ng/ml (range: 1.3- 30.1 ng/ml). The assay was validated for a
http://www.ijps.ir/article_1839.html
An Observational Safety Evaluation of Patients Treated With the NEVO Sirolimus-eluting Coronary Stent. - AdisInsightAn Observational Safety Evaluation of Patients Treated With the NEVO Sirolimus-eluting Coronary Stent. - AdisInsight
This head-to-head trial will assess the non-inferiority of NEVO sirolimus-eluting stent to the XIENCE V everolimus-eluting stent for the prevention of coronary
http://adisinsight.springer.com/trials/700043106?error=cookies_not_supported&code=34894da3-1300-4a91-8a3e-d6580074d5b2
Preliminary Results of the Hydroxyapatite Nonpolymer-Based Sirolimus-Eluting Stent for the Treatment of Single De Novo Coronary...Preliminary Results of the Hydroxyapatite Nonpolymer-Based Sirolimus-Eluting Stent for the Treatment of Single De Novo Coronary...
The main finding of this first-in-human study with the non-polymer-based VES is that sirolimus can be efficiently delivered to the coronary artery without a durable polymer, as demonstrated by the minimum neointimal growth noted at QCA and IVUS.. The development of novel DES systems must be guided by 2 main rationales: 1) to achieve an improved safety profile, and 2) to improve or at least keep the efficacy profile at levels comparable to those of the existing DES devices.. The DES toxicity may be related mainly to 2 aspects: dose/type of the antiproliferative agent delivered to the coronary artery and presence/type of polymer used to carry the antiproliferative drug. In this context, the novel VES carries less than one-half of the dose of the first-generation Cypher sirolimus-eluting stent. As previously demonstrated by Nakamura et al. (22), it is possible to keep the same efficacy of the Cypher stent using 70% or even 45% of its original dose. In a study conducted by that group with 44 ...
http://interventions.onlinejacc.org/content/1/5/545
Zotarolimus eluting stent mri safetyZotarolimus eluting stent mri safety
Pubmed.ncbi.nlm.nih.gov DA: 23 PA: 10 MOZ Rank: 47. Objectives: This study sought to report the final 5-year outcomes of the ENDEAVOR IV (A Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) trial comparing the Endeavor zotarolimus-eluting stent (E-ZES) (Medtronic, Santa Rosa, California) with … ...
https://www.keyword-suggest-tool.com/search/zotarolimus+eluting+stent+mri+safety/
A Prospective Randomized Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS element) for the...A Prospective Randomized Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS element) for the...
A Prospective Randomized Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS element) for the Treatment of up to Two De Novo Coronary Artery Lesions - PLATINUM Trial
http://icahn.mssm.edu/research/clinical-trials/health-topics/vascular/09-0201
Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer did not Improve Angiographic Outcomes Compared to Everolimus-Eluting...Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer did not Improve Angiographic Outcomes Compared to Everolimus-Eluting...
Results from the PRISON IV Trial Presented at TCT 2016 and Simultaneously Published in JACC: Cardiovascular Interventions. WASHINGTON - November 2, 2016 - Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin strut sirolimus-eluting stents (Osiro SES) with a biodegradable polymer compared to thin-strut everolimus-eluting stents (Xience EES) with a durable polymer in terms of in-segment late lumen loss in successfully treated chronic total occlusions. In addition, although the rate of binary restenosis was low overall in this complex lesion subset, it was higher with the Osirio SES compared with the Xience EES.. Findings from the PRISON IV trial were reported today at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the worlds premier educational meeting specializing in interventional cardiovascular medicine. The study was also published in the ...
http://www.crf.org/crf/news-and-events/news/news/1866-hybrid-sirolimus-eluting-stents-with-biodegradable-polymer-did-not-improve-angiographic-outcomes-compared-to-everolimus-eluting-stents-with-durable-polymer
Abstract 4916: Difference in Neointimal Growth on the Stent Struts Crossing a Side Branch Between Sirolimus-Eluting Stent and...Abstract 4916: Difference in Neointimal Growth on the Stent Struts Crossing a Side Branch Between Sirolimus-Eluting Stent and...
Background: A bifurcation lesion has been demonstrated to be the high risk lesion for late stent thrombosis (LST) following drug-eluting stent implantation, resulting from disturbed laminar blood flow and delayed endothelialization of unapposed stent struts. We examined differences in neointimal growth on the stent struts crossing a side branch between sirolimus-eluting stent (SES) and bare-metal stent (BMS) using optical coherence tomography (OCT)... Methods and Results: Of the 41 stents (34 cases) implanted across side branches, 70 struts of 28 SES and 23 struts of 13 BMS, which crossed over a side branch, were analyzed 9 months after stent implantation using OCT. Ten of 28 SES were also analyzed after 3 months. Neointimal growth around the unapposed struts, extending from the adjacent vessel wall, was classified into either complete or incomplete coverage of struts. Neointimal thickness (NIT) on struts was also measured. At 9-month follow-up, complete coverage was observed in 45 struts of SES ...
http://circ.ahajournals.org/content/118/Suppl_18/S_960.1
Diagnostic challenges of respiratory adverse events during everolimus treatmentDiagnostic challenges of respiratory adverse events during everolimus treatment
Everolimus has important clinical activity in various malignancies, but its use can be complicated by respiratory adverse events. Important everolimus-induced respiratory adverse events are interstitial lung disease (ILD) and infections, either typical or opportunistic. Furthermore, non-everolimus-related respiratory events can occur. Due to the non-specific presentation of most of these respiratory disorders, it is often not possible to differentiate between these causes on clinical and radiological grounds only. Considering the potential fatal nature of opportunistic infections, these are especially important to recognize. To be able to distinguish between ILD and (opportunistic) infections as the underlying cause, an aggressive diagnostic workup, including bronchoalveolar lavage, should be performed in patients treated with everolimus who develop respiratory disease. We report three cases of severe opportunistic pulmonary infections during everolimus treatment, concerning two Pneumocystis ...
https://repository.ubn.ru.nl/handle/2066/137780
lymphedema from sirolimus treatment [Lymphedema People]lymphedema from sirolimus treatment [Lymphedema People]
Journal of Drugs in Dermatology, March, 2006 by Lindsey Warino, James Libecco Abstract Cancer is a major cause of death in immunosuppressed transplant patients. Therefore, sirolimus is frequently used in these patients for its immunosuppressive and antineoplastic properties. However, a variety of cutaneous side effects have resulted from sirolimus therapy. Consequently, dermatologists must be aware of such adverse events and understand the risks and benefits of discontinuing therapy. Introduction Sirolimus (Rapamycin) is an immunosuppressive agent often used in combination with cyclosporine and corticosteroids in renal transplant patients. In contrast to the calcineurin inhibitors, sirolimus, a macrocyclic lactone isolated from Streptomyces Hygroscopicus, has no effect on calcineurin activity. (1-15) Rather, it acts to suppress cytokine-driven T cell proliferation and inhibits the progression from G1 to the S phase of the cell cycle. Not only is sirolimus used for its immunosuppressive ...
http://www.lymphedemapeople.com/wiki/doku.php?id=lymphedema_from_sirolimus_treatment
Sirolimus (Rapamycin, Rapamune) - NephCure Kidney International ®
Sirolimus weakens your immune system, which increases chances of getting an infection. Watch closely for signs of infection such as a fever, chills, cough, and sore throat. Contact your doctor right away if you notice any signs of infection.. You should not receive any immunizations (vaccines) without your doctors approval.. Sirolimus may make your skin more likely to sunburn. Make sure to cover your skin while outside. You should also use sunscreen with an SPF of 30 or higher to prevent sunburn.. Avoid grapefruit and grapefruit juice while taking sirolimus. They may increase the sirolimus level in your blood and make you more susceptible to certain side effects.. Sirolimus may cause birth defects if it is taken at the time of conception or during pregnancy.. Many other medications may change the blood levels of sirolimus in your body. Check with your doctor before taking any other medicines (prescription, non-prescription, herbal, or natural products).. *Note: The decision to prescribe a ...
https://nephcure.org/livingwithkidneydisease/treatment-options/sirolimus-rapamycin-rapamune/
RePub, Erasmus University Repository: Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights...RePub, Erasmus University Repository: Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights...
Patients with diabetes mellitus have less favourable outcomes after percutaneous coronary intervention (PCI) than non-diabetics. We performed a subgroup analysis of the multicentre RAVEL trial to examine the impact of the sirolimus-eluting stent (SES) on outcomes in diabetic patients. The RAVEL study randomized 238 patients to treatment with either sirolimus-eluting or bare metal stents. Forty-four patients were diabetic; 19 received sirolimus-eluting stents and 25 were treated with bare metal stents. The differences in outcomes between diabetic and non-diabetic patients treated with SES (n=101) were also assessed. Follow-up angiography was performed at 6 months. Major adverse cardiac events (MACE) defined as death, myocardial infarction (MI), or target lesion revascularization (TLR) were analysed at 12-month follow-up. Six-month in-stent late lumen loss was significantly lower for the diabetic SES than the bare stent group (0.07+/-0.2 vs 0.82+/-0.5mm; P,0.001) and similar to that in ...
https://repub.eur.nl/pub/10290
OpenEmory | Search ResultsOpenEmory | Search Results
Rationale: Sirolimus-eluting coronary stents (SESs) and paclitaxel-eluting coronary stents (PESs) are used to reduce restenosis but have different sites of action. The molecular targets of sirolimus overlap with those of the peroxisome proliferator-activated receptor (PPAR)γ agonist rosiglitazone (RSG) but the consequence of this interaction on endothelialization is unknown. Objective: Using the New Zealand white rabbit iliac model of stenting, we examined the effects of RSG on SESs, PESs, and bare metal stents endothelialization. Methods and Results: Animals receiving SESs, PESs, or bare metal stents and either RSG (3 mg/kg per day) or placebo were euthanized at 28 days, and arteries were evaluated by scanning electron microscopy. Fourteen-day organ culture and Western blotting of iliac arteries and tissue culture experiments were conducted. Endothelialization was significantly reduced by RSG in SESs but not in PESs or bare metal stents. Organ culture revealed reduced vascular endothelial ...
https://open.library.emory.edu/publications/search/?keywords=scienc&keywords=technolog&subject=Health+Sciences%2C+General&author=Finn,%20Aloke
A Prospective, Randomized, Multi-center Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for...A Prospective, Randomized, Multi-center Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for...
This head-to-head noninferiority trial is comparing the efficacy and tolerability of a platinum chromium everolimus-eluting coronary stent system [PROMUS
http://adisinsight.springer.com/trials/700056502?error=cookies_not_supported&code=fe5650b9-9571-4e1c-ae50-aa2d49003811
A phase Ib study Combining the mTOR inhibitor everolimus (RAD001) with low-dose cytarabine In untreated elderly AML [Abstract] ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
https://www.ctsu.ox.ac.uk/publications/930249
Studies show everolimus-eluting stent implantation reduces restenosis and repeat revasculariztion
Additionally, no patient in the calcified group suffered from stent thrombosis up to 3 years after PCI, while two thrombotic complications occurred in the noncalcified group. Although large population studies with long-term follow-up are mandatory, the authors concluded that EES implantation for calcified culprit lesions appears to be safe up to 3 years. This study also demonstrated that the rates of in-stent ABR (4.3%) and ID-TLR (5.9%) at 6 months for calcified culprit lesions are remarkably lower than that in previous BMS studies, in which these rates ranged from 12 to 23% and from 18 to 23%, respectively, suggesting that EES implantation is more effective for calcified culprit lesions than BMS implantation ...
http://www.rxpgnews.com/research/Studies-show-everolimus-eluting-stent-implantation-reduces-restenosis-and-repeat-revasculariztion_436074.shtml
China Sirolimus Eluting Coronary Stent - China Sirolimus Eluting Coronary Stent, Drug Eluting StentChina Sirolimus Eluting Coronary Stent - China Sirolimus Eluting Coronary Stent, Drug Eluting Stent
China Sirolimus Eluting Coronary Stent, Find details about China Sirolimus Eluting Coronary Stent, Drug Eluting Stent from Sirolimus Eluting Coronary Stent - Yilson Medical Technology Co., Ltd.
http://yilson.en.made-in-china.com/product/zqBQYwIlrehy/China-Sirolimus-Eluting-Coronary-Stent.html
The Representative Porcine Model for Human Cardiovascular Disease : Figure 5The Representative Porcine Model for Human Cardiovascular Disease : Figure 5
Figure 5: (a) X-rays of longitudinally cut rabbit iliac arteries at 21 days after placement of overlapping ZES, SES, and PES. The extent of stent coverage by endothelial cells was greatest with ZES, with almost complete coverage in the proximal and distal segments and significantly greater coverage in the overlapped segment compared with SES and PES. (b) Photomicrographs showing the amount of neointimal thickness at 28 days after placement of Endeavor zotarolimus-eluting stents (ZESs), Cypher sirolimus-eluting stents (SESs), Taxus paclitaxel-eluting stents (PESs), and Driver bare metal stents (BMSs) in rabbit iliac arteries. With SES, there were focally uncovered stent struts, which were associated with inflammation consisting of heterophils or eosinophils and giant cells. Adapted from [49 ...
https://www.hindawi.com/journals/bmri/2011/195483/fig5/
ISRCTN - ISRCTN54216890: Substitution of calcineurin inhibitors with sirolimus on left ventricular hypertrophy (LVH) of renal...ISRCTN - ISRCTN54216890: Substitution of calcineurin inhibitors with sirolimus on left ventricular hypertrophy (LVH) of renal...
All patients started CNI therapy. Subjects with chronic allograft nephropathy were switched to sirolimus, whereas patients not having chronic allograft nephropathy continued CNI and served as controls (non-randomised trial). The dose of sirolimus was titrated every other week in order to maintain trough levels between 5 and 15 mg/ml ...
http://www.isrctn.com/ISRCTN54216890
A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis | Journal of Ophthalmic...A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis | Journal of Ophthalmic...
The purpose of this study is to elicit the role of oral low-dose sirolimus as a corticosteriod-sparing agent for active uveitis. A retrospective, interventional case series was performed by reviewing the clinical records of all patients treated with oral, low-dose sirolimus (1-4 mg daily) for severe uveitis. Data reviewed included symptomatic improvement, Snellen best-corrected visual acuity, corticosteroid requirement, sirolimus levels, intraocular inflammation, spectral-domain optical coherence tomography, and fluorescein angiogram. Primary outcome measures were determined by the ability to decrease the intraocular inflammation, corticosteroid requirement, and frequency of flares. Eight patients with varied diagnoses were treated with oral low-dose sirolimus for severe, chronic uveitis between 2008 and 2010. In four of the eight patients, there was an improvement of all primary outcome measures. While sirolimus monotherapy was successful in only one patient, a sirolimus/methotrexate combination was
https://joii-journal.springeropen.com/articles/10.1007/s12348-010-0015-5
Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines | BMC Immunology | Full TextEffects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines | BMC Immunology | Full Text
Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and its derivative, everolimus, are potent immunosuppressive and antiproliferative drugs. Inflammatory diseases are characterized by immunological dysfunction, and monocyte recruitment underlies the mechanism of cell damage. Chemokines attract inflammatory cells to sites of inflammation. Interleukin-8 (IL-8/CXCL8); the monocyte chemoattractant protein-1 (MCP-1/CCL2); the regulated on activation, normal T cell expressed, presumably secreted protein (RANTES/CCL5); the macrophage inflammatory protein (MIP)-1α (CCL3); and MIP-1β (CCL4) are involved in the pathogenesis of inflammation. However, whether mTOR inhibitors moderate the production of chemokines in monocytes remains unclear. A human monocyte cell line, THP-1, and primary monocytes obtained from human volunteers, were stimulated using lipopolysaccharide (LPS), and then treated with sirolimus. The expression of the MCP-1, RANTES, IL-8, MIP-1α, MIP-1β, and TNF-α proteins was
https://bmcimmunol.biomedcentral.com/articles/10.1186/s12865-014-0037-0/figures/1
Predictors of in-stent restenosis and stent thrombosis after DES implantationPredictors of in-stent restenosis and stent thrombosis after DES implantation
The duration but not the intensity of an inflammatory response to the implantation of sirolimus-eluting coronary stents may predict the restenosis ...
https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2013/Predictors-of-in-stent-restenosis-and-stent-thrombosis-after-DES-implantation
Plus itPlus it
Purpose: Mammalian target of rapamycin (mTOR) inhibitors mediate AKT activation through a type 1 insulin-like growth factor receptor (IGF-1R)-dependent mechanism. Combining the mTOR inhibitor temsirolimus with cixutumumab, a fully human IgG1 monoclonal antibody directed against IGF-1R, was expected to enhance mTOR-targeted anticancer activity by modulating resistance to mTOR inhibition. Objectives of this Phase I study were to evaluate the tolerability and activity of temsirolimus and cixutumumab. Experimental Design: Patients in sequential cohorts (3+3 design) received escalating doses of temsirolimus with cixutumumab weekly for 28 days. At MTD, 21 patients were randomized into three separate drug sequence treatment groups for serial blood draws and FDG-PET/CT scans for pharmacodynamic analyses (PD). Results: Forty-two patients with advanced cancer (19M/23F, median age = 53, median number of prior therapies = 4) were enrolled. MTD was reached at cixutumumab, 6 mg/kg IV and temsirolimus, 25 mg ...
http://clincancerres.aacrjournals.org/content/early/2011/07/12/1078-0432.CCR-10-2979
Comparisons of the effects of stent eccentricity on the neointimal hyperplasia between Sirolimus-eluting stent versus...Comparisons of the effects of stent eccentricity on the neointimal hyperplasia between Sirolimus-eluting stent versus...
Fingerprint Dive into the research topics of Comparisons of the effects of stent eccentricity on the neointimal hyperplasia between Sirolimus-eluting stent versus Paclitaxel-eluting stent. Together they form a unique fingerprint. ...
https://yonsei.pure.elsevier.com/en/publications/comparisons-of-the-effects-of-stent-eccentricity-on-the-neointima/fingerprints/
Cardiomyopathy | Rapamycin Treatment for Age Related DiseasesCardiomyopathy | Rapamycin Treatment for Age Related Diseases
There is evidence that rapamycin improves age-related deterioration of cardiac function in laboratory mice. Our study provides the first evidence that rapamycin may partially reverse age-related heart dysfunction in dogs by improving measures of both diastolic and systolic functions...All three outcomes (EF, FS and E/A ratio) showed trends toward improved function following rapamycin treatment and two of them (FS and E/A ratio) reached statistical significance. It appears that FS improvement was most prominent in rapamycin-treated dogs with lowever baseline values, while dogs that had higher values at baseline did not improve as much in response to rapamycin. This may suggest that degree of decline already present in each individual will determine degree of improvement. (greater initial decline, greater improvement).. ...
https://rapamycintherapy.com/cardiomyopathy-1
angiotensis receptor neprilysin inhibitorangiotensis receptor neprilysin inhibitor
This weeks topics include favorable lipid-level trends in U.S. adults, an angiotensin receptor neprilysin inhibitor for patients with HF and preserved systolic ejection fraction, and a long-term safety comparison of the Zotarolimus-eluting and Sirolimus-eluting coronary stents.. ...
https://blogs.jwatch.org/cardioexchange/tag/angiotensis-receptor-neprilysin-inhibitor/
Potential of 131I-anti-TLR5 mAb for noninvasive assessment of monitoring rapamycin treated allograft efficiency (TRAN1P.936) |...Potential of 131I-anti-TLR5 mAb for noninvasive assessment of monitoring rapamycin treated allograft efficiency (TRAN1P.936) |...
Background Toll-like receptor 5 (TLR5) is a potentially target related with immunosuppressant rapamycin. Our aim was to evaluate 131I-anti-TLR5 mAb for non-invasive in vivo graft visualization and quantification in rapamycin treated allogeneic transplantation model compared with nonspecific tracer 18F-FDG. Methods Labeling, binding and stability studies were performed. Allografted BALB/c mice were divided into rapamycin-treated and non-treated group, respectively. In vivo dynamic whole-body phosphor-autoradiography and ex vivo biodistribution studies were conducted. Results Phosphor-autoradiography imaging showed clear graft localization from 12 h onward after 131I-anti-TLR5 mAb injection,significantly higher graft uptake in rapamycin-treated group. Pretreatment with anti-TLR5 mAb blocked graft uptake,which were consistent with ex vivo biodistribution studies. As the nonspecific radiotracer, high 18F-FDG uptake was only observed in non-treated allorejection group, not in treated group. The ...
http://www.jimmunol.org/content/194/1_Supplement/140.18
Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell...Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell...
Results: We enrolled 108 patients; 51 received sunitinib and 57 everolimus. Of these, 89 patients had evaluable plasma for 23 angiokines. At the final data cutoff, 87 PFS and 62 mortality events had occurred. Angiokines that were independently adversely prognostic for OS were osteopontin (OPN), hepatocyte growth factor (HGF), and VCAM-1, and these were also associated with poor-risk disease. Stromal derived factor 1 was associated with improved survival. OPN was also significantly associated with worse PFS. No statistically significant angiokine-treatment outcome interactions were observed for sunitinib or everolimus. OPN, HGF, TIMP-1, VCAM-1, PDGF-AA, and IL6 levels increased with progression on everolimus, while OPN, PlGF, TIMP-1, VEGF, and soluble VEGFR-2 and VCAM-1 increased with progression on sunitinib. ...
https://clincancerres.aacrjournals.org/content/early/2021/03/23/1078-0432.CCR-20-4504.abstract
BOLERO-3: Everolimus Might Help Patients Overcome Trastuzumab ResistanceBOLERO-3: Everolimus Might Help Patients Overcome Trastuzumab Resistance
Adding the mTOR inhibitor everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer, and in the process, provided clues to the origin of trastuzumab resistance.
http://www.onclive.com/publications/obtn/2013/july-2013/bolero-3-everolimus-might-help-patients-overcome-trastuzumab-resistance
Right coronary artery diverticulosis 4 years after sirolimus-eluting stent implantation associated with very late stent...Right coronary artery diverticulosis 4 years after sirolimus-eluting stent implantation associated with very late stent...
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you dont have an account you can just enter your email address in the email box below ...
http://heart.bmj.com/content/99/21/1627.alerts
Sirolimus | Rapamycin | CAS#53123-88-9 | Immunosuppressant | MedKooSirolimus | Rapamycin | CAS#53123-88-9 | Immunosuppressant | MedKoo
Sirolimus, also known as rapamycin, is a natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production..
http://www.medkoo.com/products/4500
Pet dogs on rapamycin are pictures of health | GerosciencePet dogs on rapamycin are pictures of health | Geroscience
In the lab, rapamycin is a star geroprotector. In addition to boosting lifespan even when used in late life, its also been found specifically to help prevent cancer, shore up the aging cardiovascular system, and stem cognitive decline. These benefits all derive from suppressing activity of the enzyme mTOR, a regulator of cell growth and survival with some less than desirable side effects on cancers and oxidative stress, among others.. But is rapamycin safe enough for chronic use in humans? Since the drug is well-known to surgeons as an immunosuppressant useful for preventing transplant rejection, fears that it would lead to immune dysfunction have thwarted its path to broad acceptance as a recommendable anti-aging therapy. In particular, previous use in humans has yielded reports of mouth ulcers, diabetes-like symptoms and low platelet count. Like its longevity benefits, these side effects are also thought to derive from rapamycins suppression of mTOR. But evidence surrounding mTORs effects ...
http://geroscience.com/pet-dogs-rapamycin/
Eyetube.net : Sirolimus for Chronic AMDEyetube.net : Sirolimus for Chronic AMD
Raj Maturi, MD, reviews a study evaluating intravitreal sirolimus therapy for chronic age-related macular degeneration. The study compared central subfield thickness data of patients who received monotherapy sirolimus versus those who continued with their current anti-VEGF regimen.
http://eyetube.net/series/daily-coverage-asrs-sanfrancisco-2016/ihodo/?sa=amd-disease-education
ESC Congress 2019: Biotronik beats Abbott at target lesion failure - MassDeviceESC Congress 2019: Biotronik beats Abbott at target lesion failure - MassDevice
Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when it comes to target lesion failure, according to data from a clinical trial.. The randomized, controlled BioSTEMI trial was the first direct comparison between the two drug-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI). Biotronik announced the results at the European Society of Cardiology Congress in Paris. In 2016, Berlin-based Biotronik claimed the Orsiro device had the edge over Xience in a heart attack subgroup study.. The 12-month study at Geneva University Hospitals included 1,300 patients with acute myocardial infarction. Orsiro had an incidence of 4% target lesion failure (TLF) at 12 months compared to Xiences 6%. The difference in TLF was caused by lower rates of clinically indicated target lesion revascularization in patients treated with Orsiro, compared to Xience. The results were published in The Lancet.. The BioSTEMI trial proves what the ...
https://www.massdevice.com/esc-congress-2019-biotronik-beats-abbott-at-target-lesion-failure/
Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus...Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus...
array(2) { [153359]=> object(eZ\Publish\Core\Repository\Values\Content\Content)#5367 (3) { [fields:protected]=> array(42) { [title]=> array(1) { [eng-GB]=> object(eZ\Publish\Core\FieldType\TextLine\Value)#5358 (1) { [text]=> string(146) Biodegradable polymer Everolimus-eluting SYNERGY stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial } } [url_title]=> array(1) { [eng-GB]=> object(eZ\Publish\Core\FieldType\TextLine\Value)#5356 (1) { [text]=> string(38) SENIOR a randomised single-blind trial } } [visibility_date]=> array(1) { [eng-GB]=> object(eZ\Publish\Core\FieldType\Date\Value)#5354 (2) { [date]=> NULL [stringFormat]=> string(7) l d F Y } } [meta_title]=> array(1) { [eng-GB]=> object(eZ\Publish\Core\FieldType\TextLine\Value)#5352 (1) { [text]=> string(146) Biodegradable polymer Everolimus-eluting SYNERGY stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial } } ...
https://www.pcronline.com/PCR-Publications/Young-EAPCI-PCR-Journal-Club/Endeavour-zotarolimus-eluting-stent-reduces-stent-thrombosis-and-improves-clinical-outcomes-compared-with-cypher-sirolimus-eluting-stent
New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World...New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World...
Registry Analysis Published in Journal Heart Finds Taxus StentImplan... ...MIAMI LAKES Fla. June 4 2007 /PRNewswire via COMTEX NewsNetwork/ -...The authors of the analysis sought to identify risk factors forsympto... The major new finding of this study was that the use of theTaxus Ste...,New,Study,Suggests,Better,Patient,Outcomes,with,CYPHER,Sirolimus-Eluting,Coronary,Stent,than,with,Taxus,Stent,in,Real-World,Clinical,Settings,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
http://www.bio-medicine.org/medicine-technology/New-Study-Suggests-Better-Patient-Outcomes-with-CYPHER-0ASirolimus-Eluting-Coronary-Stent-than-with-Taxus-Stent-in-0AReal-World-Clinical-Settings-471-1/
Sirolimus | South Tees Hospitals NHS Foundation TrustSirolimus | South Tees Hospitals NHS Foundation Trust
Sirolimus is a compound produced by the bacteria Streptomyces hygroscopicus. Sirolimus inhibits the response to interleukin-2 (IL-2) and thereby blocks activation of T- and B-cells. In contrast, tacrolimus inhibits the production of IL-2. Sirolimus limits the immune response and helps to prevent organ rejection by inhibiting immune cell activation and proliferation, and antibody production.. The chief advantage sirolimus has over calcineurin inhibitors is that it has low renal toxicity. Transplant patients maintained on calcineurin inhibitors long-term tend to develop impaired kidney function or even chronic renal failure; this can be avoided by using sirolimus instead. It is particularly advantageous in patients with kidney transplants for hemolytic-uremic syndrome, as this disease is likely to recur in the transplanted kidney if a calcineurin-inhibitor is used.. Sirolimus can be taken orally and it is absorbed from the gastrointestinal tract, concentrations peak in the blood within 1 - 2 hours ...
https://www.southtees.nhs.uk/services/pathology/tests/sirolimus/
Randomized Trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI) | JACC: Journal of...Randomized Trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI) | JACC: Journal of...
This study shows that use of SES resulted in a significantly lower rate of angiographic binary restenosis than BMS in patients with acute ST-segment elevation MI who underwent angioplasty with or without thrombolysis. Sirolimus-eluting stents also led to a higher rate of 1-year event-free survival.. These findings extend and confirm the positive finding of SES in stable patients to patients with ST-segment elevation MI. In the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent vs. Abciximab and Bare-Metal Stent in Myocardial Infarction) trial (2), 175 patients with ST-segment elevation MI were randomized to receive single high-dose bolus of tirofiban plus SES or abciximab plus BMS. However, the randomization design was primarily based on economic considerations, with the hope that the lower cost of tirofiban would offset the cost of SES, and binary stent restenosis was not the primary end point, which it was in our study.. Recently, 2 randomized trials specifically studied ...
http://www.onlinejacc.org/content/49/19/1924
TCT-321 Definite and probable stent thrombosis after revascularization with drug-eluting stents with a biodegradable polymer....TCT-321 Definite and probable stent thrombosis after revascularization with drug-eluting stents with a biodegradable polymer....
Definite stent thrombosis definition maximizes specificity, but it may be insufficiently sensitive to capture completely this relatively rare event. Sensitivity can be increased by including probable stent thrombosis in the analysis. There is limited head-to-head data on late stent thromboses for drug-eluting stents with biodegradable polymers. In accordance with the Academic Research Consortium we assessed definite and probable stent thrombosis events in the SORT OUT VII trial, among patient treated with the thin strut cobalt-chromium sirolimus-eluting Orsiro stent (Biotronik, Bülach, Switzerland) and the stainless steel biolimus-eluting Nobori stents (Terumo, Tokyo, Japan). ...
http://www.onlinejacc.org/content/68/18_Supplement/B133.1
The REMEDEE-OCT Study: An Evaluation of the Bioengineered COMBO Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary...The REMEDEE-OCT Study: An Evaluation of the Bioengineered COMBO Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary...
OBJECTIVES The aim of the present study was to evaluate vascular healing of the bioengineered COMBO Dual Therapy Stent compared with a cobalt-chromium (CoCr) everolimus-eluting stent (EES) as assessed by optical coherence tomography in patients with acute coronary syndromes. BACKGROUND CD34+ cells promote endothelial repair after vascular injury. The bioengineered COMBO Dual Therapy Stent combines CD34+ cell-capturing technology with abluminal sirolimus release, but more data from clinical studies evaluating the vascular response are needed. METHODS In a prospective randomized multicenter clinical trial, 60 patients with acute coronary syndromes were randomized 1:1 to COMBO or CoCr EES implantation. The primary endpoint was the percentage of uncovered stent struts per stent. Stent assessment by optical coherence tomography was performed at baseline and at 60 days, followed by independent core laboratory analysis. RESULTS The percentage of uncovered struts per stent was higher with the COMBO than ...
https://www.zora.uzh.ch/id/eprint/150139/
The VEGF pathway in patients with pancreatic neuroendocrine tumors: efficacy of everolimus by baseline marker level, and...The VEGF pathway in patients with pancreatic neuroendocrine tumors: efficacy of everolimus by baseline marker level, and...
Background RADIANT-3 was a phase III study investigating the effect of the mammalian target of rapamycin inhibitor everolimus on progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (pNET; Yao et al, NEJM, 2011). Everolimus significantly improved PFS compared with placebo (11 vs 4.6 months, P < .001). Here we investigate the predictive and prognostic effect of soluble VEGF pathway biomarkers among patients treated in this study.. Methods Baseline plasma levels of VEGF-A, PlGF, sVEGFR1, and sVEGFR2 were determined by ELISA using multiplexed MSD platform. The optimal cutoffs for these markers were explored using the survival tree analysis method. Interaction of treatment and baseline marker status (< or ≥ cutoff) was analyzed using a Cox proportional hazards model to assess predictive effects of these markers. P values and hazard ratios for prognostic effects were obtained using stratified log rank test and Cox proportional hazards model, stratified by ...
http://oncologypro.esmo.org/Topics/Endocrine-Cancers/Neuroendocrine-Cancers/The-VEGF-pathway-in-patients-with-pancreatic-neuroendocrine-tumors-efficacy-of-everolimus-by-baseline-marker-level-and-prognostic-and-predictive-effect-analyses-from-radiant-3
Drug-eluting stents to prevent stent thrombosis and restenosis. - NextBio article
Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results ...
http://www.nextbio.com/b/search/article.nb?id=26567863
Cureus | Early Restenosis of Sirolimus-eluting Stent: An Unusual Case of a Hyperthyroid PatientCureus | Early Restenosis of Sirolimus-eluting Stent: An Unusual Case of a Hyperthyroid Patient
The presentation of atherosclerosis with concomitant hyperthyroidism is not uncommon. Hyperthyroidism predisposes to worse cardiovascular pathologies like systolic hypertension, atrial fibrillation, and hypercoagulability. Drug-eluting stents, on the other hand, have emerged as a miracle treatment choice for patients having atherogenic conditions. They have the highest success rates when it comes to minimizing in-stent restenosis (ISR) during short-term follow-up. There is scarce literature that assesses the correlation of multinodular goiter (MNG) to ISR, especially in Pakistan, and thus any probable association between the two is left untouched. We report a case of a 57-year-old female who is a known hyperthyroid with a massive MNG, presenting with worsening chest pain. She had undergone sirolimus-eluting stent (SES) implantation in left anterior descending artery (LAD) six months back. Cardiac catheterization confirmed restenosis of the SES in the LAD, along with the occlusion of left circumflex and
https://www.cureus.com/articles/26248-early-restenosis-of-sirolimus-eluting-stent-an-unusual-case-of-a-hyperthyroid-patient
Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular...Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular...
TCT 2013 presentation of data planned -. DURHAM, N.C., September 30, 2013 - Micell Technologies, Inc. today announced that a peer reviewed article discussing imaging and clinical results of the DESSOLVE I trial of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) was accepted for publication on the JACC Cardiovascular Interventions website. The paper, First-in-Human Evaluation of a Bioabsorbable Polymer-Coated Sirolimus- Eluting Stent: Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries), is planned to also appear in the October 2013 issue of JACC Cardiovascular Interventions.. The article concluded that, upon 18 months follow-up, the MiStent SES - an absorbable polymer-coated, cobalt chromium, sirolimus-eluting stent - was associated with a low and stable in-stent late lumen loss, complete strut coverage, and no stent ...
http://www.micell.com/micell-technologies-announces-dessolve-manuscript-accepted-publication-american-college-cardiologys-cardiovascular-interventions-journal/
Oscillatory mTOR inhibition and Treg increase in kidney transplantation
Intracellular metabolic pathways dependent upon the mammalian target of rapamycin (mTOR) play a key role in immune-tolerance control. In this study, we focused on long-term mTOR-dependent immune-modulating effects in kidney transplant recipients undergoing conversion from calcineurin inhibitors (CNI) to mTOR inhibitors (everolimus) in a 1-year follow-up. The conversion to everolimus is associated with a decrease of neutrophils and of CD8(+) T cells. In addition, we observed a reduced production of interferon (IFN)-γ by CD8(+) T cells and of interleukin (IL)-17 by CD4(+) T lymphocytes. An increase in CD4(+) CD25(+) forkhead box protein 3 (FoxP3)(+) [regulatory T cell [(Treg )] numbers was also seen. Treg increase correlated with a higher proliferation rate of this regulatory subpopulation when compared with the CD4(+) FoxP3(-) effector counterpart. Basal phosphorylation level of S6 kinase, a major mTOR-dependent molecular target, was substantially maintained in patients treated with everolimus. ...
https://www.iris.unisa.it/handle/11386/4650869
Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondriaTacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria
1. Tacrolimus and sirolimus are potent immunosuppressors used in transplantation. Tacrolimus has been suspected to alter mitochondrial respiration of different tissues but sirolimus has not been evaluated. 2. We evaluated the in vitro effect of tacrolimus and sirolimus on oxidative phosphorylation o …
https://pubmed.ncbi.nlm.nih.gov/12540528/?dopt=Abstract
ASCO GI: Drug-Refractory Neuroendocrine Tumors Respond to Oral mTOR Inhibitor | Medpage TodayASCO GI: Drug-Refractory Neuroendocrine Tumors Respond to Oral mTOR Inhibitor | Medpage Today
SAN FRANCISCO -- Chemotherapy-refractory pancreatic neuroendocrine tumors had durable responses and stable disease in patients treated with the mTOR inhibitor RAD001, an open-label study showed.
https://www.medpagetoday.com/meetingcoverage/ascogi/12541
Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients<...
TY - JOUR. T1 - Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. AU - Kushwaha, Sudhir S.. AU - Raichlin, Eugenia. AU - Sheinin, Yuri. AU - Kremers, Walter K.. AU - Chandrasekaran, Krishnaswamy. AU - Brunn, Gregory J.. AU - Platt, Jeffrey L.. PY - 2008/11. Y1 - 2008/11. N2 - Aims: The cellular mechanisms underlying cardiac hypertrophy may result from changes in cardiac myocyte growth and differentiation. We tested whether sirolimus, an immunosuppressive agent that inhibits mTOR, a protein that regulates cell division and differentiation, might modify cardiac hypertrophy after cardiac transplantation. Methods and results: Fifty-eight cardiac transplant recipients were withdrawn from treatment with calcineurin inhibitors (CNIs) and treated with sirolimus. Eighty-three control subjects were maintained on CNIs. After 12 months, left ventricular (LV) mass decreased from 196.15 ± 48.28 to 182.21 ± 43.56 g (P = 0.05) and LV mass index from 99.25 ± ...
https://experts.nebraska.edu/en/publications/sirolimus-affects-cardiomyocytes-to-reduce-left-ventricular-mass-
Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents: A Pooled Analysis From the SPIRIT II (A Clinical...Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents: A Pooled Analysis From the SPIRIT II (A Clinical...
This pooled analysis suggests a significant and sustained reduction in TVF and MACE among patients treated with EES compared with PES at 3-year follow-up. Furthermore, EES demonstrated improved efficacy and safety over time, with robust reductions in ischemia-driven target lesion revascularization and target vessel revascularization as well as significant and sustained reductions in MI and composite death or MI. It should be noted that the present study is underpowered to definitively examine low-frequency adverse events such as stent thrombosis, MI, and death and comparative trials with emerging DES are required to determine the optimal platform for specific patient and lesion subtypes, particularly patients with diabetes. Based on available data, and the improved clinical outcomes demonstrated in patients receiving EES compared with those receiving PES, EES is an attractive drug-eluting stent choice for clinicians.. ...
http://www.acc.org/latest-in-cardiology/journal-scans/2011/01/28/19/59/clinical-follow-up-3-years-after-ees-and-pes
Aging | Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice - Figure
The use of rapamycin to extend lifespan and delay age-related disease in mice is well-established despite its potential to impair glucose metabolism which is driven partially due to increased hepatic gluconeogenesis. We tested whether a combination therapeutic approach using rapamycin and metformin could diminish some of the known metabolic defects caused by rapamycin treatment in mice. In genetically heterogeneous HET3 mice, we found that chronic administration of encapsulated rapamycin by diet caused a measurable defect in glucose metabolism in both male and female mice as early as 1 month after treatment. In female mice, this defect was alleviated over time by simultaneous treatment with metformin, also by diet, such that females treated with both drugs where indistinguishable from control mice during glucose tolerance tests. While rapamycin-mediated glucose intolerance was unaffected by metformin in males, we found metformin prevented rapamycin-mediated reduction in insulin and leptin concentrations
https://www.aging-us.com/figure/101401/f5
Trial Data Shows Superior Efficacy of Promus Element Compared to Xience V | DAICTrial Data Shows Superior Efficacy of Promus Element Compared to Xience V | DAIC
March 29, 2012 - Two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the safety and effectiveness of the Promus Element and Xience V everolimus-eluting coronary stents demonstrated superior efficacy of the Promus. The results were presented at the American College of Cardiology (ACC) Annual Scientific Session by Gregg W. Stone, M.D., professor of medicine and director of research and education at the Center for Interventional Vascular Therapy at Columbia University Medical Center/New York-Presbyterian Hospital. He was the global principal investigator of the trial. The outcomes reported at 12 months remained comparable at two years for the two stents. However, an additional landmark analysis of outcomes from year one to year two demonstrated superior efficacy of the Promus Element during this 12-month period of follow-up. The Promus Element platinum chromium stent continues to demonstrate excellent safety and effectiveness with low rates of cardiac death, myocardial ...
https://www.dicardiology.com/article/trial-data-shows-superior-efficacy-promus-element-compared-xience-v
Everolimus treatment option for tuberous sclerosis patientsEverolimus treatment option for tuberous sclerosis patients
Researchers have shown that the immunosuppressant everolimus provides a potential new treatment option for patients with tuberous sclerosis and associated angiomyolipomas.
https://www.news-medical.net/news/20130125/Everolimus-treatment-option-for-tuberous-sclerosis-patients.aspx
Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translationRapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation
The immunosuppressant drug rapamycin blocks progression of the cell cycle at the G1 phase in mammalian cells and yeast. Here we show that rapamycin inhibits cap-dependent, but not cap-independent, translation in NIH 3T3 cells. Cap-dependent translation is also specifically reduced in extracts from r …
https://pubmed.ncbi.nlm.nih.gov/8599949/?dopt=Abstract
Everolimus plus Exemestane Significantly Prolongs Remission in BOLERO-2 - The ASCO PostEverolimus plus Exemestane Significantly Prolongs Remission in BOLERO-2 - The ASCO Post
Adding an inhibitor of mammalian target of rapamycin (mTOR) to an aromatase inhibitor more than doubled the time to disease progression in patients with advanced, treatment-refractory breast cancer in the phase III BOLERO-2 trial, whose updated results were presented at the San Antonio Breast Cancer Symposium by Gabriel Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, Houston.1. We believe these results underline the fact that everolimus [Afinitor] is the first agent to significantly enhance the efficacy of hormonal therapy in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, and could represent a paradigm shift in the management of this patient population, Dr. Hortobagyi predicted.. Virtually all patients with ER-positive advanced disease develop resistance to hormonal therapies, and finding a means of overcoming this resistance is the subject of strong research efforts. Resistance to hormonal therapy in breast cancer has been associated ...
http://www.ascopost.com/issues/february-15-2012-supplement/everolimus-plus-exemestane-significantly-prolongs-remission-in-bolero-2/
Hyperlipid: Physiological insulin resistanceHyperlipid: Physiological insulin resistance
There are two types of diabetes, which at advanced stages may become similar. Insulin resistance may develop in type I diabetes (due to high glucose), whereas insulin insufficiency in type II diabetes (due to loss of beta-cells). Both types of diabetes lead to complications. In comparison, starvation diabetes [28] is only superficially resembles either type of diabetes. Also, diabetes-like symptoms may occur in rapamycin-treated mice and animals with genetically inhibited insulin/IGFI signaling (Fig. 3). To encompass all these cases, I suggest the term type 0 (zero) or benevolent diabetes. It is possible that some patients with diabetes have inactivating mutations in the insulin/IGFI pathway and thus suffer from benevolent diabetes. Furthermore, the condition can be imitated by chronic administration of rapamycin at least in some strains of mice. Both calorie restriction and rapamycin extend life span in mice. Rapamycin prevents retinopathy and nephropathy. Also CR prevents type II diabetes ...
http://high-fat-nutrition.blogspot.com/2007/10/physiological-insulin-resistance.html?showComment=1279412325619
Hyperlipid: Physiological insulin resistanceHyperlipid: Physiological insulin resistance
There are two types of diabetes, which at advanced stages may become similar. Insulin resistance may develop in type I diabetes (due to high glucose), whereas insulin insufficiency in type II diabetes (due to loss of beta-cells). Both types of diabetes lead to complications. In comparison, starvation diabetes [28] is only superficially resembles either type of diabetes. Also, diabetes-like symptoms may occur in rapamycin-treated mice and animals with genetically inhibited insulin/IGFI signaling (Fig. 3). To encompass all these cases, I suggest the term type 0 (zero) or benevolent diabetes. It is possible that some patients with diabetes have inactivating mutations in the insulin/IGFI pathway and thus suffer from benevolent diabetes. Furthermore, the condition can be imitated by chronic administration of rapamycin at least in some strains of mice. Both calorie restriction and rapamycin extend life span in mice. Rapamycin prevents retinopathy and nephropathy. Also CR prevents type II diabetes ...
http://high-fat-nutrition.blogspot.com/2007/10/physiological-insulin-resistance.html?showComment=1221626880000
New Generation Drug-Eluting Stent Shows Equivalent Efficacy | EmaxHealth
Nine months after the procedure, the numbers of deaths, heart attacks and repeat interventions required because of renewed blood vessel narrowing were equivalent in both treatment groups (9.2% of patients in the biolimus-eluting stent group and 10.5% of patients in the sirolimus-eluting stent group). In the one in four patients given an angiogram, the degree of blood vessel narrowing at the site of stent implantation was also equivalent in both treatment groups.. The drug-eluting stent is designed to treat narrowing of coronary arteries which is one of the principal causes of coronary artery disease. Once implanted, it uses the strength of its cylindrical mesh wall to keep the artery widened and maintain blood flow, and gradually releases its drug into the surrounding tissues. The role of the drug is to inhibit restenosis, a common problem following stent implantation, whereby excessive tissue forms around the stent and may negate the benefit that it provides. First-generation drug-eluting ...
https://www.emaxhealth.com/24/1/24400.html
Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System IV - American College of CardiologyClinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System IV - American College of Cardiology
The primary endpoint of TLF (cardiac death, target vessel MI, ischemia-driven target lesion revascularization [TLR]) was significantly lower in the EES arm compared with the PES arm (4.2% vs. 6.8%, hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.46-0.82, p = 0.001 for superiority). This was driven primarily by a significant reduction in ischemia-driven TLR (2.5% vs. 4.6%, HR 0.55, 95% CI 0.38-0.78, p = 0.001). Cardiac death or target vessel MI were similar between the two arms (2.2% vs. 3.2%, p = 0.09). All-cause mortality was similar (1.0% vs. 1.3%, p = 0.61), but EES was associated with a significant reduction in MI (1.9% vs. 3.1%, p = 0.02). EES was also associated with a significant reduction in stent thrombosis (Academic Research Consortium [ARC] or probable) at 1 year, as compared with PES (0.2% vs. 0.8%, p = 0.004). The greatest impact of TLF reduction was noted in patients without diabetes mellitus (DM) (p , 0.05). Two-year follow-up data were available for 3,578 patients (97%). ...
http://www.acc.org/latest-in-cardiology/clinical-trials/2011/04/19/15/06/spirit-iv
Ultrasound results - Symptoms, Treatments and Resources for Ultrasound resultsUltrasound results - Symptoms, Treatments and Resources for Ultrasound results
Ultrasound results - MedHelps Ultrasound results Center for Information, Symptoms, Resources, Treatments and Tools for Ultrasound results. Find Ultrasound results information, treatments for Ultrasound results and Ultrasound results symptoms.
http://www.medhelp.org/tags/show/45219/Ultrasound-results
Immunosuppressants FK506 and rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period...
TY - JOUR. T1 - Immunosuppressants FK506 and rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation. AU - Miyamoto, Suzanne. AU - Safer, Brian. PY - 1999/12/15. Y1 - 1999/12/15. N2 - FK506 and rapamycin are immunosuppressants that interfere with T cell activation. FK506 inhibits early events of T cell activation such as the induction of cytokine transcription, whereas rapamycin inhibits later interleukin 2 signalling events. However, both reagents either directly or indirectly reduce protein synthesis. Therefore a kinetic study was conducted in human primary T lymphocytes examining increased synthesis of proteins stimulated by either ionomycin + phorbol myristate acetate (PMA) or PMA alone. Three patterns of protein expression were observed. Synthesis of one group of proteins had enhanced synthesis with FK506, but reduced synthesis with rapamycin. A second group had reduced synthesis with rapamycin and either no change or a slight ...
https://ucdavis.pure.elsevier.com/en/publications/immunosuppressants-fk506-and-rapamycin-have-different-effects-on-
AntiAging Cancer Drug - Ageing: A midlife longevity drug?AntiAging Cancer Drug - Ageing: A midlife longevity drug?
Inhibition of the TOR signalling pathway by genetic or pharmacological intervention extends lifespan in invertebrates, including yeast, nematodes and fruitflies1, 2, 3, 4, 5; however, whether inhibition of mTOR signalling can extend lifespan in a mammalian species was unknown. Here we report that rapamycin, an inhibitor of the mTOR pathway, extends median and maximal lifespan of both male and female mice when fed beginning at 600 days of age. On the basis of age at 90% mortality, rapamycin led to an increase of 14% for females and 9% for males. The effect was seen at three independent test sites in genetically heterogeneous mice, chosen to avoid genotype-specific effects on disease susceptibility. Disease patterns of rapamycin-treated mice did not differ from those of control mice. In a separate study, rapamycin fed to mice beginning at 270 days of age also increased survival in both males and females, based on an interim analysis conducted near the median survival point. Rapamycin may extend ...
http://www.natap.org/2012/HIV/010212_08.htm
Eosinophilic rash secondary to temsirolimus<...
TY - JOUR. T1 - Eosinophilic rash secondary to temsirolimus. AU - Gandhi, Mona. AU - Kuzel, Timothy. AU - Lacouture, Mario. PY - 2009/1/1. Y1 - 2009/1/1. N2 - We present a case of a 73-year-old female with metastatic renal cell carcinoma, clear cell histologic subtype, who developed pruritic rash after 2 weeks of 25 mg weekly infusions of temsirolimus. Rash was located on bilateral antecubital areas and posterior knees. Skin biopsy showed spongiotic dermatitis with eosinophils. Based on history and clinical examination, a diagnosis of drug rash secondary to temsirolimus was made. Temsirolimus is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR). Inhibition of mTOR kinase results in cell cycle arrest, antiangiogenesis, and apoptosis. The mechanism of skin toxicity is unknown; however, it can be hypothesized that there is a direct inhibitory effect on signaling pathways that regulate cell growth and tissue repair. The mTOR kinase inhibitor temsirolimus has shown great promise ...
https://www.scholars.northwestern.edu/en/publications/eosinophilic-rash-secondary-to-temsirolimus
SirolimusSirolimus
... seems to lower the cancer risk in some transplant patients. Sirolimus was shown to inhibit the progression of dermal ... Sirolimus blocks this pathway. The safety and efficacy of sirolimus treatment of LAM were investigated in clinical trials that ... Sirolimus is used to treat vascular malformations. Treatment with sirolimus can decrease pain and the fullness of vascular ... Sirolimus is a relatively new medical therapy for the treatment of vascular malformations in recent years, sirolimus has ...
https://en.wikipedia.org/wiki/Sirolimus
Streptomyces rapamycinicusStreptomyces rapamycinicus
... produces sirolimus. List of Streptomyces species LPSN bacterio.net UniProt Deutsche Sammlung von ...
https://en.wikipedia.org/wiki/Streptomyces_rapamycinicus
MTOR inhibitorsMTOR inhibitors
In 2003, the U.S. Food and Drug Administration approved sirolimus-eluting coronary stents, which are used in patients with ... "CYPHER Sirolimus-eluting Coronary Stent - P020026". Food and Drug Administration. Retrieved 25 September 2012. "Torisel". ... Ridaforolimus (AP23573, MK-8669), or deforolimus, is another rapamycin analogue that is not a prodrug for sirolimus. Like ... The bacterial natural product rapamycin or sirolimus, a cytostatic agent, has been used in combination therapy with ...
https://en.wikipedia.org/wiki/MTOR_inhibitors
Cypher stentCypher stent
"CYPHER™ Sirolimus-eluting Coronary Stent - P020026". FDA.gov. U.S. Food and Drug Administration. Retrieved 1 Aug 2016. "J&J to ... Sirolimus: Anti-proliferative effects "Learn about CYPHER Stent, the latest advance in stent technology". Cordis Corporation. ... An anti-rejection-type medication, sirolimus, helps to limit the overgrowth of normal cells while the artery heals which ...
https://en.wikipedia.org/wiki/Cypher_stent
LymphangiomaLymphangioma
Sirolimus is used to treat lymphangioma . Treatment with sirolimus can decrease pain and the fullness of venous malformations, ... Sirolimus is a relatively new medical therapy for the treatment of vascular malformations, in recent years, sirolimus has ... Sirolimus (rapamycin, trade name Rapamune) is a macrolide compound. It has immunosuppressant and antiproliferative functions in ... "Sirolimus in the treatment of vascular anomalies." https://www.jvascsurg.org/article/S0741-5214(19)32236-0/fulltext, Journal of ...
https://en.wikipedia.org/wiki/Lymphangioma
CedeceaCedecea
H. Mawardi; M. Pavlakis; D.S. Mandelbrot; S.B. Woo (2010). "Sirolimus oral ulcer with Cedecea davisae superinfection". Transpl ... Mawardi, H., Pavlakis, M., Mandelbrot, D., Woo, S. B. (2010). Sirolimus oral ulcer with Cedecea davisae superinfection. Transpl ...
https://en.wikipedia.org/wiki/Cedecea
HivesHives
Sirolimus and mycophenolate have less evidence for their use in the treatment of chronic hives but reports have shown them to ... Morgan M (2009). "Treatment of refractory chronic urticaria with sirolimus". Arch Dermatol. 145 (6): 637-9. doi:10.1001/ ... Immunosuppressants used for CU include cyclosporine, tacrolimus, sirolimus, and mycophenolate. Calcineurin inhibitors, such as ... At this point, anti-inflammatory medications (dapsone, sulfasalazine), immunosuppressants (cyclosporin, sirolimus) or other ...
https://en.wikipedia.org/wiki/Hives
GenousGenous
The Combo Dual Therapy Stent is a coronary stent that combines Genous with an antiproliferative, biodegradable sirolimus drug ... Sirolimus-Eluting Stent Found 'Safe,' and 'Effective.'" Cardiology News. "Dual-Therapy Stenting: The Next Step in the Evolution ...
https://en.wikipedia.org/wiki/Genous
TemsirolimusTemsirolimus
It is a derivative and prodrug of sirolimus. Temsirolimus is a specific inhibitor of mTOR and interferes with the synthesis of ... Though temsirolimus shows activity on its own, it is also known to be converted to sirolimus (rapamycin) in vivo; therefore, ...
https://en.wikipedia.org/wiki/Temsirolimus
Cardiac allograft vasculopathyCardiac allograft vasculopathy
Medications including sirolimus and everolimus can slow disease progression. A repeat heart transplantation may be required. ... On detection of CAV, medications including mTOR inhibitors sirolimus and everolimus have been shown to slow disease progression ...
https://en.wikipedia.org/wiki/Cardiac_allograft_vasculopathy
ZotarolimusZotarolimus
It is a semi-synthetic derivative of sirolimus (rapamycin). It was designed for use in stents with phosphorylcholine as a ...
https://en.wikipedia.org/wiki/Zotarolimus
Streptomyces isolatesStreptomyces isolates
Sirolimus (Rapamycin), ascomycin, and tacrolimus were isolated from Streptomyces. Pimecrolimus is a derivative of ascomycin. ...
https://en.wikipedia.org/wiki/Streptomyces_isolates
Timeline of tuberous sclerosisTimeline of tuberous sclerosis
"Sirolimus in Treating Patients With Angiomyolipoma of the Kidney". ClinicalTrials.gov (NIH). 21 November 2006. Retrieved 10 ... 2002 Treatment with rapamycin (sirolimus) was found to shrink tumours in the Eker rat (TSC2) and mouse (TSC1) models of ... "Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial (The MILES Trial)". ClinicalTrials.gov (NIH). 6 ...
https://en.wikipedia.org/wiki/Timeline_of_tuberous_sclerosis
Kidney transplantationKidney transplantation
Some recipients may instead take ciclosporin, sirolimus, or azathioprine. The risk of early rejection of the transplanted ... These food products are known to interact with the transplant medications, specifically tacrolimus, cyclosporin and sirolimus; ...
https://en.wikipedia.org/wiki/Kidney_transplantation
Valentín FusterValentín Fuster
Poon, Michael; Badimon, Juan Jose; Fuster, Valentin (2002-02-16). "Overcoming restenosis with sirolimus: from alphabet soup to ... Poon, Michael; Badimon, Juan Jose; Fuster, Valentin (2002). "Viewpoint Overcoming restenosis with sirolimus: From alphabet soup ...
https://en.wikipedia.org/wiki/Valentín_Fuster
Autoimmune lymphoproliferative syndromeAutoimmune lymphoproliferative syndrome
Sirolimus may not be as immune suppressive in normal lymphocytes as other agents. Some patients have had improvement in immune ... Hypothetically, Sirolimus may have lower risk of secondary cancers as opposed to other immune suppressants and requires ... 2009). "Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome". ... It may cause hypogammaglobulinemia (transient) requiring IVIgG replacement.[citation needed] Sirolimus (rapamycin, rapamune) ...
https://en.wikipedia.org/wiki/Autoimmune_lymphoproliferative_syndrome
Fibro-adipose vascular anomalyFibro-adipose vascular anomaly
Sirolimus has been effective in improving the quality of life in some people with FAVA. "Fibro-Adipose Vascular Anomaly (FAVA ... Erickson J, McAuliffe W, Blennerhassett L, Halbert A (November 2017). "Fibroadipose vascular anomaly treated with sirolimus: ...
https://en.wikipedia.org/wiki/Fibro-adipose_vascular_anomaly
History of invasive and interventional cardiologyHistory of invasive and interventional cardiology
"Cordis' CYPHER TM Sirolimus-eluting Stent Receives CE Mark Approval" (PDF). Cordis Corporation. April 15, 2002. Archived from ... Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007). "A pooled analysis of data comparing sirolimus-eluting stents ... Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo ... 2002). "A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization". N Engl J ...
https://en.wikipedia.org/wiki/History_of_invasive_and_interventional_cardiology
Immunosuppressive drugImmunosuppressive drug
Everolimus is an analog of sirolimus and also is an mTOR inhibitor. Zotarolimus is a semi-synthetic derivative of sirolimus ... Sirolimus (rapamycin, trade name Rapamune) is a macrolide lactone, produced by the actinomycete bacterium Streptomyces ... Therefore, sirolimus acts synergistically with ciclosporin and, in combination with other immunosuppressants, has few side ... In a similar manner, Sirolimus prevents B cell differentiation into plasma cells, reducing production of IgM, IgG, and IgA ...
https://en.wikipedia.org/wiki/Immunosuppressive_drug
Percutaneous coronary interventionPercutaneous coronary intervention
The first two drug-eluting stents to be utilized were the paclitaxel-eluting stent and the sirolimus-eluting stent, both of ... Most current FDA-approved drug-eluting stents use sirolimus (also known as rapamycin), everolimus and zotarolimus. Biolimus A9- ... Claessen BE, Henriques JP, Dangas GD (2010). "Clinical studies with sirolimus, zotarolimus, everolimus, and biolimus A9 drug- ...
https://en.wikipedia.org/wiki/Percutaneous_coronary_intervention
NeurofibromaNeurofibroma
Sirolimus, a compound that inhibits mTOR signalling, is being studied to treat plexiform neurofibromas. The combination of ... Clinical trial number NCT00652990 for "Sirolimus to Treat Plexiform Neurofibromas in Patients With Neurofibromatosis Type I" at ... erlotinib with sirolimus was studied to treat low-grade gliomas. Early research has shown potential for using the c-kit ... ClinicalTrials.gov Clinical trial number NCT00634270 for "A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis ...
https://en.wikipedia.org/wiki/Neurofibroma
Robert ProvenzanoRobert Provenzano
Impact of Avoiding Loading Dose of Sirolimus on Wound Complication After Kidney Transplant. A Single Center Experience, Ayran, ... Safety and Efficacy of Sirolimus, Low Dose Tacrolimus and Early Steroid Withdrawal in Patients with Cadaveric Renal Allographs ... M., Jabri, M., El-Ghoroury, M., Oh, H., Provenzano, R., Impact of Avoiding Loading Dose of Sirolimus on Wound Complication ... A Comparative Study, Nagrecha, N., El-Ghoroury, M., Provenzano, R., Safety and Efficacy of Sirolimus, Low Dose Tacrolimus and ...
https://en.wikipedia.org/wiki/Robert_Provenzano
NephrologyNephrology
... thymoglobulin and sirolimus. Newer, so-called "biologic drugs" or monoclonal antibodies, are also used in these conditions and ...
https://en.wikipedia.org/wiki/Nephrology
Dual therapy stentDual therapy stent
The sirolimus drug reduces the risk of stent restenosis through inhibiting the formation of neointima while the anti-CD34 ... Antiproliferative drugs like sirolimus and paclitaxel were used in the first-generation drug-eluting stents to inhibit the ... The COMBO stent is a pro-healing stent with sirolimus drug elution and anti-CD3 monoclonal antibodies that has enhanced degree ... The COMBO stent's enhanced endothelization is due to the sirolimus drug that reduces the risk of stent restenosis and the ...
https://en.wikipedia.org/wiki/Dual_therapy_stent
EverolimusEverolimus
It also may have a similar role to sirolimus in kidney and other transplants. Although, sirolimus had generated fears over use ... It is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of ... Everolimus treatment of mice results in reduced metabolic side effects compared to sirolimus. Use During Pregnancy and ...
https://en.wikipedia.org/wiki/Everolimus
Diffuse neonatal hemangiomatosisDiffuse neonatal hemangiomatosis
For example, the mTOR inhibitor, Sirolimus, can be used to treat diffuse neonatal hemangiomatosis. It is important to note that ...
https://en.wikipedia.org/wiki/Diffuse_neonatal_hemangiomatosis
Koenens tumorKoenen's tumor
... topical application of sirolimus, i.e. rapamycin, (1% solution). Some of the latter methods have been used in order to preserve ... Topical Sirolimus Electrofulguration and Excision". Skin Appendage Disorders. 7 (1): 66-70. doi:10.1159/000511743. PMC 7879313 ...
https://en.wikipedia.org/wiki/Koenen's_tumor
P-glycoproteinP-glycoprotein
... and sirolimus. Decreased P-gp expression has been found in Alzheimer's disease brains. Altered P-gp function has also been ...
https://en.wikipedia.org/wiki/P-glycoprotein
LymphangioleiomyomatosisLymphangioleiomyomatosis
... led to successful use of rapamycin analog sirolimus in clinical trials and FDA approval of sirolimus for treatment of LAM. TSC1 ... Sirolimus is effective for chylous effusions and most experts believe it should be used as the first line of therapy. Imaging ... An FDA-approved drug for treatment of LAM, the mTOR inhibitor sirolimus, is available for stabilization of lung function ... MILES data supports the use of sirolimus in patients who have abnormal lung function (i.e. FEV1. ...
https://en.wikipedia.org/wiki/Lymphangioleiomyomatosis
SAFit2SAFit2
Sirolimus Tacrolimus Gaali S, Kirschner A, Cuboni S, Hartmann J, Kozany C, Balsevich G, et al. (January 2015). "Selective ...
https://en.wikipedia.org/wiki/SAFit2
Sirolimus: MedlinePlus Drug InformationSirolimus: MedlinePlus Drug Information
Sirolimus: learn about side effects, dosage, special precautions, and more on MedlinePlus ... while taking sirolimus, and for 12 weeks after stopping sirolimus. If you become pregnant while taking sirolimus, call your ... Before taking sirolimus,. *tell your doctor and pharmacist if you are allergic to sirolimus, any other medications, or any of ... Sirolimus is used in combination with other medications to prevent rejection of kidney transplants. Sirolimus is in a class of ...
https://medlineplus.gov/druginfo/meds/a602026.html
Registry Outcomes Support Ultrathin Sirolimus StentRegistry Outcomes Support Ultrathin Sirolimus Stent
... the ultra-thin sirolimus-eluting device was associated with lower target lesion revascularization rates, new registry data ... For the TLR end point, however, the investigators saw a significant difference in favor of the sirolimus-eluting stent (1.6% vs ... Rates of myocardial infarction (MI) were numerically but not statistically higher in patients who received the sirolimus- ... There were some differences in procedural characteristics, however, with patients who received the sirolimus-eluting device ...
http://www.medscape.com/viewarticle/913442
Lymphedema in patients treated with sirolimus: 15 cases]Lymphedema in patients treated with sirolimus: 15 cases]
... and without disappearance after sirolimus discontinuation. Pathophysiological mechanisms remain unclear. Lymphedema management ... Sirolimus is associated with upper and/or lower limb lymphedema, without predominance of sex, ... Lymphedema in patients treated with sirolimus: 15 cases] Rev Med Interne. 2019 Mar;40(3):151-157. doi: 10.1016/j.revmed.2018.04 ... Background: Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor used after organ transplantation and to treat ...
https://pubmed.ncbi.nlm.nih.gov/29752013/
Meta-Analysis: Sirolimus-Eluting Stents Best for Small Vessel PCI | MedPage TodayMeta-Analysis: Sirolimus-Eluting Stents Best for Small Vessel PCI | MedPage Today
Meta-Analysis: Sirolimus-Eluting Stents Best for Small Vessel PCI. - But newer-generation stents not included in comparisons. ... Early generation sirolimus-eluting stents (SES) lead the pack for percutaneous coronary intervention (PCI) in small coronary ...
https://www.medpagetoday.com/cardiology/pci/58600
Sirolimus | Harvard Catalyst Profiles | Harvard CatalystSirolimus | Harvard Catalyst Profiles | Harvard Catalyst
"Sirolimus" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5- ... This graph shows the total number of publications written about "Sirolimus" by people in Harvard Catalyst Profiles by year, and ... Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties. ...
https://connects.catalyst.harvard.edu/Profiles/display/Concept/Sirolimus
Use of sirolimus (rapamycin) to treat refractory Crohns disease | GutUse of sirolimus (rapamycin) to treat refractory Crohn's disease | Gut
Use of sirolimus (rapamycin) to treat refractory Crohns disease Message subject: (Your Name) has forwarded a page to you from ...
https://gut.bmj.com/content/57/9/1294.share
Clinical Use of the mTOR Pathway Inhibitor Sirolimus (rapamycin) to Treat Children with Autoimmune Lymphoproliferative Syndrome...Clinical Use of the mTOR Pathway Inhibitor Sirolimus (rapamycin) to Treat Children with Autoimmune Lymphoproliferative Syndrome...
Sirolimus has revolutionized the treatment of ALPS and is quickly becoming the standard of care as a single agent targeted ... Prior to using sirolimus for ALPS, there was no effective treatment that could improve the lymphoproliferative and autoimmune ... Clinical trials are underway at the Center for Childhood Cancer Research to evaluate the use of sirolimus as a treatment for ... Pilot clinical studies with as many as 50 pediatric ALPS patients revealed that sirolimus treatments resulted in a complete and ...
https://www.chop.edu/cccr/area-of-study/clinical-use-mtor-pathway-inhibitor-sirolimus-rapamycin-treat-children-autoimmune
Atacand and Sirolimus drug interactions, a phase IV clinical study of FDA data - eHealthMe
Drug interactions are found among 3 people who take Atacand and Sirolimus. See what the interactions are and for which people. ... What is Sirolimus?. Sirolimus has active ingredients of sirolimus. eHealthMe is studying from 9,391 Sirolimus users for its ... Sirolimus (9,391 reports). Browse all drug interactions of Atacand and Sirolimus:. a b c d e f g h i j k l m n o p q r s t u v ... Browse all interactions between Sirolimus and drugs from A to Z:. a b c d e f g h i j k l m n o p q r s t u v w x y z How the ...
https://www.ehealthme.com/drug-interaction/atacand/sirolimus/
Response to sirolimus in a case of diffuse congenital hyperinsulinaemic hypoglycaemia due to homozygous KCNJ11 mutation | BMJ...Response to sirolimus in a case of diffuse congenital hyperinsulinaemic hypoglycaemia due to homozygous KCNJ11 mutation | BMJ...
Response to sirolimus in a case of diffuse congenital hyperinsulinaemic hypoglycaemia due to homozygous KCNJ11 mutation ... Response to sirolimus in a case of diffuse congenital hyperinsulinaemic hypoglycaemia due to homozygous KCNJ11 mutation ... Our case highlights the response to sirolimus in a case of congenital hyperinsulinaemia (CHI) due to KCNJ11 mutation and severe ... He was started on tablet sirolimus, after which the child was off all other medication and was euglycaemic. However, he ...
https://casereports.bmj.com/content/15/11/e252708
Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis | Orphanet Journal of Rare Diseases | Full TextEfficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis | Orphanet Journal of Rare Diseases | Full Text
... who received sirolimus were retrospectively reviewed. Low-dose sirolimus was defined as any dose that maintained mean blood ... Sirolimus showed efficacy in a phase 3 trial of patients with lymphangioleiomyomatosis, but the optimal dose remains unclear. ... We investigated the efficacy and safety of low-dose compared with conventional-dose sirolimus. Clinical data of 39 patients ... 94.7%, p = 0.605). Low-dose sirolimus may stabilise lung function decline in lymphangioleiomyomatosis patients, but its ...
https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0946-8
Low-Dose Rapamycin (Sirolimus) Effects in Autosomal Dominant Polycystic Kidney Disease: An Open-Label Randomized Controlled...Low-Dose Rapamycin (Sirolimus) Effects in Autosomal Dominant Polycystic Kidney Disease: An Open-Label Randomized Controlled...
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363: 820-829, 2010pmid:20581391. ... High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 326-333, 2007pmid: ... Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 21: 1031-1040, 2010pmid:20466742. ... Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 23: 842-853, 2012pmid: ...
https://cjasn.asnjournals.org/content/9/5/881.long
Very Late Stent Fracture Associated With a Sirolimus-eluting Stent - McMaster Experts
Very Late Stent Fracture Associated With a Sirolimus-eluting Stent Academic Article ...
https://experts.mcmaster.ca/display/publication1019105
Primary Endpoint Results Of The SAVE Study - Sirolimus As Therapeutic Approach To UVEItis: A Randomized Study To Assess The...Primary Endpoint Results Of The SAVE Study - Sirolimus As Therapeutic Approach To UVEItis: A Randomized Study To Assess The...
None of the adverse events (AE) were deemed to be related to sirolimus. At M6, VA improved in 39% (SCJ=43%; IVT=36%) and ... Sirolimus has demonstrated bioactivity by reducing vitreous haze and cells, improving VA, and in decreasing need for systemic ... Primary Endpoint Results Of The SAVE Study - Sirolimus As Therapeutic Approach To UVEItis: A Randomized Study To Assess The ... Primary Endpoint Results Of The SAVE Study - Sirolimus As Therapeutic Approach To UVEItis: A Randomized Study To Assess The ...
https://iovs.arvojournals.org/article.aspx?articleid=2352914
Clinical Trial on Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa): Sirolimus for Injection (Albumin Bound) -...Clinical Trial on Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa): Sirolimus for Injection (Albumin Bound) -...
This is a phase Ⅰb/Ⅱ multi-center study of safety and efficacy of Sirolimus for Injection (Albumin-bound) in patients with ... Intervention Name: Sirolimus for Injection (Albumin Bound) Description: Sirolimus for injection (Albumin-bound), intravenously ... Description: Sirolimus for injection (Albumin-bound) will be administered intravenously on day 1and day 8 every 21 days (a ... This is a phase Ⅰb/Ⅱ multi-center study of safety and efficacy of Sirolimus for Injection (Albumin-bound) in patients with ...
https://ichgcp.net/clinical-trials-registry/NCT05625919
Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient<...
Then, sirolimus at a dose of 1.0 mg/d was added to the tacrolimus-based regimen. The T-bil level rapidly decreased to 5.4 mg/dL ... Then, sirolimus at a dose of 1.0 mg/d was added to the tacrolimus-based regimen. The T-bil level rapidly decreased to 5.4 mg/dL ... Then, sirolimus at a dose of 1.0 mg/d was added to the tacrolimus-based regimen. The T-bil level rapidly decreased to 5.4 mg/dL ... Then, sirolimus at a dose of 1.0 mg/d was added to the tacrolimus-based regimen. The T-bil level rapidly decreased to 5.4 mg/dL ...
https://kyushu-u.pure.elsevier.com/en/publications/effectiveness-of-sirolimus-in-combination-with-cyclosporine-again
Sirolimus for Lymphangioleiomyomatosis
Andy Shorr discusses a study that evaluated the efficacy and safety of sirolimus in lymphangioleiomyomatosis, a rare and ... Sirolimus has toxicities, and more adverse advents were seen in the patients who took sirolimus compared with those who took ... Over the course of a year, the investigators saw that the patients assigned to sirolimus had improvements not only in FEV1 but ... Patients who had formerly taken sirolimus and who had improvement in lung function regressed over the course of a year, and the ...
http://www.staging.medscape.com/viewarticle/744918
Can Sirolimus-eluting stents tolerate some degree of geographic miss? - Dr C RAGHU Cardiologist
Call us now if you are in a medical emergency need, we will reply swiftly and provide you with a medical aid. ...
https://test.drraghu.com/can-sirolimus-eluting-stents-tolerate-some-degree-of-geographic-miss/
Procedural and long-term results of sirolimus-eluting stent in patients at high risk for restenosis<...
Dive into the research topics of Procedural and long-term results of sirolimus-eluting stent in patients at high risk for ... Presbitero P, Zavalloni D, Scatturin M, Marsico F, Pagnotta P, Boccuzzi G. Procedural and long-term results of sirolimus- ... Procedural and long-term results of sirolimus-eluting stent in patients at high risk for restenosis. In: Minerva ... Procedural and long-term results of sirolimus-eluting stent in patients at high risk for restenosis. / Presbitero, P.; ...
https://moh-it.pure.elsevier.com/en/publications/procedural-and-long-term-results-of-sirolimus-eluting-stent-in-pa
LONG-TERM OUTCOME OF THE UNRESTRICTED USE OF EVEROLIMUS-ELUTING STENTS COMPARED TO SIROLIMUS-ELUTING STENTS AND PACLITAXEL...
LONG-TERM OUTCOME OF THE UNRESTRICTED USE OF EVEROLIMUS-ELUTING STENTS COMPARED TO SIROLIMUS-ELUTING STENTS AND PACLITAXEL- ... LONG-TERM OUTCOME OF THE UNRESTRICTED USE OF EVEROLIMUS-ELUTING STENTS COMPARED TO SIROLIMUS-ELUTING STENTS AND PACLITAXEL- ...
https://www.ctsu.ox.ac.uk/publications/1281203
Pediatric Heart Transplantation Medication: Vasodilators, Inotropic Agents, Pulmonary Vasodilators, Immunosuppressants, Immune...Pediatric Heart Transplantation Medication: Vasodilators, Inotropic Agents, Pulmonary Vasodilators, Immunosuppressants, Immune...
Use of sirolimus in pediatric heart transplant patients: A multi-institutional study from the Pediatric Heart Transplant Study ... Sirolimus, also known as rapamycin, is a macrocyclic lactone produced by Streptomyces hygroscopicus. It is a potent ... Sirolimus is a newer agent that works synergistically with calcineurin inhibitors. There is little published experience with ...
https://emedicine.medscape.com/article/1011927-medication
IMSEAR at SEARO: Sirolimus: a new immunosuppressant.
Sirolimus is a relatively new immunosuppressant isolated from a macrolide antibiotic. It may have a beneficial role in ... Sirolimus: a new immunosuppressant. Journal of the Association of Physicians of India. 2005 Oct; 53(): 885-90. ...
https://imsear.searo.who.int/handle/123456789/93908
Sirolimus conversion in liver transplant recipients with renal dysfunction: A prospective, randomized, single-center trial<...
Sirolimus conversion in liver transplant recipients with renal dysfunction: A prospective, randomized, single-center trial. ... Sirolimus conversion in liver transplant recipients with renal dysfunction : A prospective, randomized, single-center trial. / ... Sirolimus conversion in liver transplant recipients with renal dysfunction : A prospective, randomized, single-center trial. In ... Shenoy, S, Hardinger, KL, Crippin, J, Desai, N, Korenblat, K, Lisker-Melman, M, Lowell, JA & Chapman, W 2007, Sirolimus ...
https://jhu.pure.elsevier.com/en/publications/sirolimus-conversion-in-liver-transplant-recipients-with-renal-dy-3
SIROLIMUS - Eastern Pathology AllianceSIROLIMUS - Eastern Pathology Alliance
This website uses cookies to help improve the way the site works. These store limited data about your visit and NO personal data is stored. The amended Privacy and Electronic Communications Regulations cover the use of cookies on websites and introduce powers for the Information Commissioner to enforce these regulations. This site uses cookies to make parts of the site work better. You dont have to accept these and you may block cookies (by using the settings in your browser), however some website functionality will not then work. No personal information is stored in these cookies For full details of the types of cookies in use by this site please see our Privacy Policy page. ...
https://www.easternpathologyalliance.nhs.uk/tests/sirolimus/
Sirolimus Archives - Dose PharmacySirolimus Archives - Dose Pharmacy
All the available medications on the website entertain their own risks, benefits, and therefore individual results may differ. It is recommended to buy only those items which are prescribed ...
https://www.dosepharmacy.com/active-ingredient-drug-salt/sirolimus
Sirolimus - The Medical Etymology GlossarySirolimus - The Medical Etymology Glossary
Sirolimus, also called rapamycin, is produced by Streptomyces hygroscopicus, which was first discovered in soil samples ... Sirolimus. Sirolimus, also called rapamycin, is produced by Streptomyces hygroscopicus, which was first discovered in soil ...
https://metymology.ch/glossary/sirolimus/
Cilazapril vs Sirolimus drug - drug interactionCilazapril vs Sirolimus drug - drug interaction
Cilazapril vs Sirolimus causes Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors. ... Post Review about Cilazapril vs Sirolimus Click here to cancel reply.. Comment. ...
https://www.genericpedia.com/interaction/Cilazapril-vs-Sirolimus/
Bio-Domperidone - Uses, Side Effects, Interactions - MedBroadcast.comBio-Domperidone - Uses, Side Effects, Interactions - MedBroadcast.com
Bio-Domperidone: Domperidone belongs to the group of medications called dopamine antagonists. It is used to treat slowed movement in the gastrointestinal tract associated with diabetes and gastritis (inflammation of the stomach lining). For people with this condition, domperidone improves symptoms of nausea, vomiting, bloating, and feeling of fullness.
https://medbroadcast.com/drug/getdrug/bio-domperidone
Sirolimus market size, trends, forecast to 2029Sirolimus market size, trends, forecast to 2029
Segmentation of the sirolimus market: Sirolimus market, by distribution channel. â ¢ Hospital pharmacies. â ¢ Retail pharmacies ... â ¢ Balloons and catheters coated with Sirolimus. The Sirolimus market is segmented on the basis of product type, application, ... Visualize Sirolimus Market Using Verified Market Intelligence: - Verified Market Intelligence is our BI platform for narrative ... All of the segments of the Sirolimus market are carefully analyzed on the basis of their market share, CAGR, growth in value ...
https://stopwatchmarketing.com/sirolimus-market-size-trends-forecast-to-2029/
Sirolimus DCB Archives - Bernardo Cortese M.D.Sirolimus DCB Archives - Bernardo Cortese M.D.
Sirolimus DCBTag: Posted on 28th January 2021. 16th July 2021. by Bernardo Cortese Posted in Current research on Drug-Coated ... WEBINAR: Sirolimus-coated balloons, an appraisal on its potential advantages over paclitaxel. Watch this roundtable discussion ... DCB sponsored session at AsiaPCR 2022, Singapore: "The role of Sirolimus Coated Balloon in a wide variety of coronary artery ... To see the potential advantages of using the Sirolimus over Paclitaxel. Speakers: Antonio Colombo, Bernardo Cortese, Sandeep ...
https://www.bernardocortese.com/tag/sirolimus-dcb/
RapamycinSwitched tacrolimusStentsBiodegradable polymer sirolimus-elutiEverolimusPaclitaxelRecipientsLymphangioleiomyomatosisDoseTransplantationRejectionClinicalTabletCalcineurinPatientsInhibitorsCyclosporineRefractoryImmunosuppressantDescriptorOutcomesInteractionsDrugsTabletsPotential advantagesAdverseStudyHazeMechanismsAnalyzesTherapyCombinationMedianYear
Rapamycin11
  • Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor used after organ transplantation and to treat vascular malformations. (nih.gov)
  • They also found that targeting ALPS with the mTOR inhibitor sirolimus (rapamycin) is effective. (chop.edu)
  • Everolimus instead of Sirolimus / Rapamycin? (rapamycin.news)
  • @morlock mentioned that he's using everolimus instead of sirolimus / rapamycin, which I'm finding really interesting because its the first time I've heard of a person using everolimus. (rapamycin.news)
  • How does it compare to rapamycin / sirolimus (have you tried both? (rapamycin.news)
  • This is really interesting from two points - the price is really good - Morlock, correct me if I'm wrong, but it sounds like you got 10mg X 10, for $60, which would work out to $0.60 per mg, a pretty good price - especially for everolimus, which is much more recently off-patent than sirolimus / rapamycin. (rapamycin.news)
  • So the strategy might be to dose it higher, and a little more frequently than rapamycin / sirolimus which could theoretically result in better life extension effects. (rapamycin.news)
  • Here is the 1/2 life blood sirolimus levels you see with rapamycin vs. what you would see in everolimus. (rapamycin.news)
  • We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients. (rapamycin.news)
  • Sirolimus, also known as rapamycin, is an immunosuppressive agent that arrests the cell cycle in the G1/S phase and inhibits proliferation and migration of vascular smooth muscle cells (VSMCs). (revportcardiol.org)
  • In preclinical trials, Sirolimus (rapamycin) was shown effective in reducing tumors in mouse models of familial adenomatous polyposis and colon cancer with APC deficient tumors ( PMID: 18768809 , PMID: 20080688 ). (jax.org)
Switched tacrolimus1
  • Because the intracellular receptor of sirolimus and tacrolimus is FK506-binding protein 12, we switched tacrolimus to cyclosporine at a dose of 60 mg/d to avoid competitive inhibition between these 2 drugs. (elsevier.com)
Stents6
  • Early generation sirolimus-eluting stents (SES) lead the pack for percutaneous coronary intervention (PCI) in small coronary arteries, according to a network meta-analysis. (medpagetoday.com)
  • Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes. (harvard.edu)
  • Can Sirolimus-eluting stents tolerate some degree of geographic miss? (drraghu.com)
  • Large clinical trials have shown that sirolimus-eluting stents (SES) have reduced restenosis rate to 0-9% in lesions at low-moderate risk. (elsevier.com)
  • To examine the 1-year safety and clinical outcomes associated with the post-marketing early unselected use of sirolimus-eluting stents (SES) in the United States. (ochsner.org)
  • Ricardo Seabra Gomes was the pioneer of PCI in Portugal, performing the first balloon angioplasty in May 1984, 5 the first stent implantation in June 1990 and the first DES implantation - of sirolimus-eluting stents (SES) - in April 2002. (revportcardiol.org)
Biodegradable polymer sirolimus-eluti1
  • Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: 5-year results of the TARGET â ¡ trial]. (bvsalud.org)
Everolimus3
  • Larger dosage required for everolimus than sirolimus to maintain same blood. (rapamycin.news)
  • Conversion from sirolimus to everolimus in kidney transplant recipients. (rapamycin.news)
  • Known allergy to sirolimus, everolimus or zotarolimus. (who.int)
Paclitaxel2
  • First-generation DES using sirolimus or paclitaxel were first introduced in 2002. (revportcardiol.org)
  • Tanto los BLD como los SLD suelen contener paclitaxel o sirolimus, drogas que al liberarse lentamente tienen el objetivo de inhibir la proliferación y migración de las células musculares lisas y la formación de matriz extracelular. (bvsalud.org)
Recipients6
  • OBJECTIVE: We examined the occurrence of neoplasms among 1008 renal transplant recipients treated with a sirolimus-cyclosporine (CsA) +/- prednisone (Pred) regimen. (notifylibrary.org)
  • CONCLUSION: Renal transplant recipients treated with the sirolimus-CsA +/- Pred combination showed a low incidence of tumors of similar types as those encountered with other regimens. (notifylibrary.org)
  • Switching from a calcineurin inhibitor (CNI) to sirolimus for immunosuppression may decrease the risk of nonmelanoma skin cancer (NMSC) in kidney transplant recipients with a history of NMSC, according to researchers. (renalandurologynews.com)
  • The antifibrotic effects of sirolimus are seen in animal models but have not been described in liver transplant recipients. (elsevier.com)
  • We reviewed 1274 liver recipients from 2002 to 2010 and identified a cohort of HCV recipients exposed to sirolimus as primary immunosuppression (SRL Cohort) and an HCV Control Group of recipients who had never received sirolimus. (elsevier.com)
  • This is the first study among liver transplant recipients with recurrent HCV to describe the positive impact of sirolimus in respect of reduced fibrosis extent and rate of progression. (elsevier.com)
Lymphangioleiomyomatosis3
  • Fifteen patients (7 men, 8 women), mean age at the first visit, 56 years (range: 38-76), had a kidney transplant (n=12), liver transplant (n=1), or lymphangioleiomyomatosis (n=2) treated with sirolimus at a mean daily dose of 1.8mg were included. (nih.gov)
  • Sirolimus showed efficacy in a phase 3 trial of patients with lymphangioleiomyomatosis, but the optimal dose remains unclear. (biomedcentral.com)
  • Low-dose sirolimus may stabilise lung function decline in lymphangioleiomyomatosis patients, but its efficacy appears to be inferior to that of conventional-dose sirolimus. (biomedcentral.com)
Dose6
  • Your doctor will probably adjust your dose of sirolimus during your treatment, usually not more than once every 7 to 14 days. (medlineplus.gov)
  • We investigated the efficacy and safety of low-dose compared with conventional-dose sirolimus. (biomedcentral.com)
  • Low-dose sirolimus was defined as any dose that maintained mean blood trough levels lower than those maintained with conventional doses (5-15 ng/mL). (biomedcentral.com)
  • Therefore, we aimed to compare the efficacy and safety of low- and conventional-dose sirolimus in patients with LAM. (biomedcentral.com)
  • Then, sirolimus at a dose of 1.0 mg/d was added to the tacrolimus-based regimen. (elsevier.com)
  • This study aims to identify the right dose of sirolimus to treat people who have LAM. (nih.gov)
Transplantation1
  • These results suggest that sirolimus therapy in combination with cyclosporine may be an effective treatment against CR after liver transplantation. (elsevier.com)
Rejection2
  • Sirolimus is used in combination with other medications to prevent rejection of kidney transplants. (medlineplus.gov)
  • Sirolimus tablets are prescribed for preventing rejection of kidney transplants either alone or with other medications. (healthtekpak.com)
Clinical8
  • PARIS - Results of a large registry-based study appear to support at least some of the claims of clinical benefit with an ultra-thin sirolimus-eluting stent ( Orsiro, Biotronik). (medscape.com)
  • Given the difference in the size of the cohorts, it would be inadvisable to read too much into the numerical but not statistical superiority of the sirolimus-eluting stent for some clinical outcomes, such as in-stent restenosis and definite stent thrombosis, she cautioned. (medscape.com)
  • The aim of this study was to analyze the clinical features, lymphoscintigraphy and lymphedema outcome in patients treated with sirolimus. (nih.gov)
  • Clinical trials are underway at the Center for Childhood Cancer Research to evaluate the use of sirolimus as a treatment for refractory pediatric autoimmune diseases. (chop.edu)
  • Pilot clinical studies with as many as 50 pediatric ALPS patients revealed that sirolimus treatments resulted in a complete and durable response in over 90 percent of sirolimus-treated patients with minimal toxicity. (chop.edu)
  • The phase IV clinical study analyzes what interactions people who take Atacand and Sirolimus have. (ehealthme.com)
  • Additional clinical trials are indicated to confirm the role of locally-delivered sirolimus and to determine its appropriate dosage and frequency of administration. (arvojournals.org)
  • Clinical Efficacy Evaluation of Sirolimus in Congenital Hyperinsulinism. (cdc.gov)
Tablet2
  • Sirolimus comes as a tablet and a solution (liquid) to take by mouth. (medlineplus.gov)
  • He was started on tablet sirolimus, after which the child was off all other medication and was euglycaemic. (bmj.com)
Calcineurin1
  • Forty patients with renal dysfunction (24-hr CrCl 40-80 mL/min) were randomized to be withdrawn from the calcineurin inhibitor (CNI) and receive sirolimus (SRL) or to continue CNI (control arm). (elsevier.com)
Patients16
  • Sirolimus may cause serious side effects or death in patients who have had liver or lung transplants. (medlineplus.gov)
  • There were some differences in procedural characteristics, however, with patients who received the sirolimus-eluting device having less frequent left main procedures (2.6% vs 5.5%) and shorter total stent length (31.5 vs 35.7 mm). (medscape.com)
  • Monocentric retrospective study from January 2008 to September 2017 analyzing all consecutive patients having lymphedema occurring with sirolimus. (nih.gov)
  • The present study included 39 patients with LAM (82.1% biopsy-proven cases) treated with sirolimus between May 2011 and March 2016 at Asan Medical Center, Seoul, Republic of Korea (Fig. 1 ). (biomedcentral.com)
  • To evaluate the safety and bioactivity of sirolimus as an immunomodulatory therapeutic (IMT) agent, delivered subconjunctivally (SCJ) or intravitreally (IVT), in patients with non-infectious posterior, intermediate, or panuveitis. (arvojournals.org)
  • Locally administered (subconjunctival or intravitreal) sirolimus appears to be safe in patients with non-infectious uveitis. (arvojournals.org)
  • They performed a well-done, double-blind, randomized, controlled trial in which approximately 90 patients were randomly assigned to either sirolimus (with the drug level titrated to 5-15 ng/mL) or placebo. (medscape.com)
  • Over the course of a year, the investigators saw that the patients assigned to sirolimus had improvements not only in FEV1 but also in forced vital capacity. (medscape.com)
  • Lung function in the patients who were randomly assigned to sirolimus actually improved. (medscape.com)
  • They looked again at the rate of change and found that once patients stopped taking sirolimus, the drug's beneficial effect deteriorated and decayed very quickly. (medscape.com)
  • Patients who had formerly taken sirolimus and who had improvement in lung function regressed over the course of a year, and the trajectory of their lung function declined. (medscape.com)
  • This study clearly demonstrates that sirolimus offers an important therapeutic intervention in patients with LAM. (medscape.com)
  • For patients with LAM with abnormal/declining lung function, treatment with sirolimus rather than observation is recommended. (medscape.com)
  • For selected patients with LAM with problematic chylous effusions, treatment with sirolimus before invasive management is recommended. (medscape.com)
  • RÉSUMÉ La présente étude a examiné les connaissances et la compréhension actuelles des patients en matière de substitution par des génériques. (who.int)
  • À notre avis, la substitution par des génériques ne doit pas être mise en œuvre de manière aléatoire en raison de l'incertitude et des faibles connaissances des patients. (who.int)
Inhibitors1
  • Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors. (genericpedia.com)
Cyclosporine1
  • The target trough concentration of sirolimus and cyclosporine was set to around 15 ng/mL and 180 ng/ mL, respectively. (elsevier.com)
Refractory1
  • Topics include sirolimus in combination with tacrolimus in GVHD prophylaxis, sirolimus as primary therapy for acute GVHD, and sirolimus as a treatment for steroid-refractory acute and chronic GVHD. (bethematchclinical.org)
Immunosuppressant5
  • Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties. (harvard.edu)
  • IMSEAR at SEARO: Sirolimus: a new immunosuppressant. (who.int)
  • Sirolimus: a new immunosuppressant. (who.int)
  • Sirolimus is a relatively new immunosuppressant isolated from a macrolide antibiotic. (who.int)
  • Glenmark Pharmaceuticals announced that it has received approval from the US health regulator to market Sirolimus tablets (0.5 mg, 1 mg and 2 mg), an immunosuppressant, in the US market. (healthtekpak.com)
Descriptor1
  • Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (harvard.edu)
Outcomes1
  • In this study, McCormack and colleagues looked at the question of whether sirolimus as an immunosuppressive agent affected outcomes in this disease. (medscape.com)
Interactions2
  • Drug interactions are reported only by a few people who take Atacand and Sirolimus together. (ehealthme.com)
  • 3 people who take Atacand and Sirolimus together, and have interactions are studied. (ehealthme.com)
Drugs1
  • eHealthMe is studying from 9,391 Sirolimus users for its effectiveness, alternative drugs and more. (ehealthme.com)
Tablets1
  • tell your doctor and pharmacist if you are allergic to sirolimus, any other medications, or any of the ingredients in sirolimus tablets or solution. (medlineplus.gov)
Potential advantages1
  • The authors discuss the immunosuppressive, antitumor, and antiviral properties of sirolimus, and analyze its potential advantages over other immunosuppressors. (bethematchclinical.org)
Adverse2
  • Our case highlights the response to sirolimus in a case of congenital hyperinsulinaemia (CHI) due to KCNJ11 mutation and severe adverse event thereafter. (bmj.com)
  • None of the adverse events (AE) were deemed to be related to sirolimus. (arvojournals.org)
Study3
  • Each section of the research study is specially prepared to examine key aspects of the Sirolimus market. (stopwatchmarketing.com)
  • We have also provided Porter's Five Forces and PESTLE analysis for further study of the Sirolimus market. (stopwatchmarketing.com)
  • Prot# P00-6302: A Multicenter, Randomized, Double-Blind Study of the Sirolimus-Coated Bx Velocity? (northwestern.edu)
Haze2
  • Sirolimus solution may develop a haze when refrigerated. (medlineplus.gov)
  • Sirolimus has demonstrated bioactivity by reducing vitreous haze and cells, improving VA, and in decreasing need for systemic CS. (arvojournals.org)
Mechanisms1
  • This review summarizes the mechanisms of action of sirolimus in preventing and treating graft-versus-host disease (GVHD). (bethematchclinical.org)
Analyzes1
  • With qualitative and quantitative analyzes, we help you with in-depth and comprehensive research on the Sirolimus market. (stopwatchmarketing.com)
Therapy1
  • Sirolimus has revolutionized the treatment of ALPS and is quickly becoming the standard of care as a single agent targeted therapy for to treat children with ALPS. (chop.edu)
Combination1
  • Known hypersensitivity of the of to such Consumer from slow a in layer combination consists adequate sirolimus first may or infusions chlorhexidine be and then into have your occur with including cream. (pakapoo.online)
Median3
  • The median time between lymphedema onset and the beginning of sirolimus was 52 weeks (range: 8-232). (nih.gov)
  • Sirolimus was discontinued in 7 cases without lymphedema improvement with a median follow-up of 12 months and maintained in 8 cases. (nih.gov)
  • median treatment period, 29.6 months) who received sirolimus were retrospectively reviewed. (biomedcentral.com)
Year2
  • This graph shows the total number of publications written about "Sirolimus" by people in Harvard Catalyst Profiles by year, and whether "Sirolimus" was a major or minor topic of these publication. (harvard.edu)
  • Multivariate analysis demonstrated sirolimus as an independent predictor of minimal fibrosis at year one, and year two. (elsevier.com)